A01H1/00	0	Processes for modifying genotypes {; Plants characterised by associated natural traits} (A01H4/00 takes precedence)
A01H1/06	1	Processes for producing mutations, e.g. treatment with chemicals or with radiation (specific mutations prepared by genetic engineering on plant cell or plant tissues C12N15/00 {; process for producing transgenic plants C12N15/82})
A01K2267/0306	2	Animal model for genetic diseases
A23C19/0326	3	{Rennet produced by fermentation, e.g. microbial rennet; Rennet produced by genetic engineering}
A23C2220/202	2	Genetic engineering of microorganisms used in dairy technology
A23C2230/00	0	Aspects relating to animal feed or genotype
A23C2230/15	1	Animal milk with modified composition due to manipulation of the animal, e.g. animal milk comprising antibodies, selection of animals having specific genotypes
A23V2300/21	1	Genetic modification
A61K38/225	4	{Calcitonin gene related peptide}
A61K38/2264	4	{Obesity-gene products, e.g. leptin}
A61K39/001196	3	{Fusion proteins originating from gene translocation in cancer cells}
A61K47/67	5	{Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}
A61K48/00	0	Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K48/0091	1	{Purification or manufacturing processes for gene therapy compositions}
A61K2800/86	2	Products or compounds obtained by genetic engineering
A61L2300/258	2	Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
A61N1/36121	6	{Production of neurotransmitters; Modulation of genes expression}
A61N2005/1032	4	{Genetic optimization methods}
B01F2101/44	1	Mixing of ingredients for microbiology, enzymology, in vitro culture or genetic manipulation
C07H		SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
C07K		PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
C07K14/57527	3	{Calcitonin gene related peptide}
C07K14/5759	3	{Products of obesity genes, e.g. leptin, obese (OB), tub, fat}
C12		BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12C2200/01	1	Use of specific genetic variants of barley or other sources of fermentable carbohydrates for beer brewing
C12M21/00	0	{Bioreactors or fermenters specially adapted for specific uses (digesters for manure A01C3/023; apparatus for PCR B01L7/52; destroying or transforming solid waste B09B3/00; methods for genetic engineering C12N15/00, C12Q1/68; nucleic acid amplification reactions C12Q1/6844)}
C12M35/00	0	{Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion (machines for extracting juice from animal or plant tissue by electroplasmolysis A23N1/006, processes employing electric or wave energy B01J19/08; treatment of microorganisms or enzymes with electrical or wave energy C12N13/00; methods for cell fusion C12N15/02; introduction of foreign genetic material C12N15/87)}
C12N		MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
C12N5/10	1	Cells modified by introduction of foreign genetic material
C12N15/00	0	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
C12N15/01	1	Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
C12N15/1024	4	{In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
C12N15/1031	4	{mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
C12N15/1051	4	{Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
C12N15/1065	4	{Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
C12N15/1072	4	{Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
C12N15/1075	4	{by coupling phenotype to genotype, not provided for in other groups of this subclass}
C12N15/1082	4	{Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
C12N15/1093	4	{General methods of preparing gene libraries, not provided for in other subgroups}
C12N15/113	3	Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
C12N15/1135	4	{against oncogenes or tumor suppressor genes}
C12N15/52	3	Genes encoding for enzymes or proenzymes
C12N15/63	2	Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N15/635	3	{Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
C12N15/66	3	General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12N15/8201	5	{Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}
C12N15/8213	6	{Targeted insertion of genes into the plant genome by homologous recombination}
C12N15/8217	6	{Gene switch}
C12N15/8218	6	{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
C12N15/822	6	{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}
C12N15/8257	7	{for the production of primary gene products, e.g. pharmaceutical products, interferon}
C12N15/8265	8	{Transgene containment, e.g. gene dispersal}
C12N2015/8536	7	{Animal models for genetic diseases}
C12N15/87	2	Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N2310/111	3	spanning the whole gene, or a large part of it
C12N2320/12	2	in functional genomics, i.e. for the determination of gene function
C12N2501/34	2	Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
C12N2710/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/00043	3	viral genome or elements thereof as genetic vector
C12N2710/00062	3	by genetic engineering
C12N2710/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10043	4	viral genome or elements thereof as genetic vector
C12N2710/10062	4	by genetic engineering
C12N2710/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10143	5	viral genome or elements thereof as genetic vector
C12N2710/10162	5	by genetic engineering
C12N2710/10222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10243	5	viral genome or elements thereof as genetic vector
C12N2710/10262	5	by genetic engineering
C12N2710/10322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10343	5	viral genome or elements thereof as genetic vector
C12N2710/10362	5	by genetic engineering
C12N2710/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/12043	4	viral genome or elements thereof as genetic vector
C12N2710/12062	4	by genetic engineering
C12N2710/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/14043	4	viral genome or elements thereof as genetic vectore
C12N2710/14062	4	by genetic engineering
C12N2710/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/14143	5	viral genome or elements thereof as genetic vector
C12N2710/14162	5	by genetic engineering
C12N2710/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16043	4	viral genome or elements thereof as genetic vector
C12N2710/16062	4	by genetic engineering
C12N2710/16122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16143	5	viral genome or elements thereof as genetic vector
C12N2710/16162	5	by genetic engineering
C12N2710/16222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16243	5	viral genome or elements thereof as genetic vector
C12N2710/16262	5	by genetic engineering
C12N2710/16322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16343	5	viral genome or elements thereof as genetic vector
C12N2710/16362	5	by genetic engineering
C12N2710/16422	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16443	5	viral genome or elements thereof as genetic vector
C12N2710/16462	5	by genetic engineering
C12N2710/16522	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16543	5	viral genome or elements thereof as genetic vector
C12N2710/16562	5	by genetic engineering
C12N2710/16622	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16643	5	viral genome or elements thereof as genetic vector
C12N2710/16662	5	by genetic engineering
C12N2710/16722	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16743	5	viral genome or elements thereof as genetic vector
C12N2710/16762	5	by genetic engineering
C12N2710/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/18043	4	viral genome or elements thereof as genetic vector
C12N2710/18062	4	by genetic engineering
C12N2710/20022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/20043	4	viral genome or elements thereof as genetic vector
C12N2710/20062	4	by genetic engineering
C12N2710/22022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/22043	4	viral genome or elements thereof as genetic vector
C12N2710/22062	4	by genetic engineering
C12N2710/24022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24043	4	viral genome or elements thereof as genetic vector
C12N2710/24062	4	by genetic engineering
C12N2710/24122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24143	5	viral genome or elements thereof as genetic vector
C12N2710/24162	5	by genetic engineering
C12N2710/24222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24243	5	viral genome or elements thereof as genetic vector
C12N2710/24262	5	by genetic engineering
C12N2720/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/00043	3	viral genome or elements thereof as genetic vector
C12N2720/00062	3	by genetic engineering
C12N2720/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/10043	4	viral genome or elements thereof as genetic vector
C12N2720/10062	4	by genetic engineering
C12N2720/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12043	4	viral genome or elements thereof as genetic vector
C12N2720/12062	4	by genetic engineering
C12N2720/12122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12143	5	viral genome or elements thereof as genetic vector
C12N2720/12162	5	by genetic engineering
C12N2720/12222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12243	5	viral genome or elements thereof as genetic vector
C12N2720/12262	5	by genetic engineering
C12N2720/12322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12343	5	viral genome or elements thereof as genetic vector
C12N2720/12362	5	by genetic engineering
C12N2730/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/00043	3	viral genome or elements thereof as genetic vector
C12N2730/00062	3	by genetic engineering
C12N2730/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/10043	4	viral genome or elements thereof as genetic vector
C12N2730/10062	4	by genetic engineering
C12N2730/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/10143	5	viral genome or elements thereof as genetic vector
C12N2730/10162	5	by genetic engineering
C12N2740/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/00043	3	viral genome or elements thereof as genetic vector
C12N2740/00062	3	by genetic engineering
C12N2740/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/10043	4	viral genome or elements thereof as genetic vector
C12N2740/10062	4	by genetic engineering
C12N2740/11022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/11043	5	viral genome or elements thereof as genetic vector
C12N2740/11062	5	by genetic engineering
C12N2740/12022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/12043	5	viral genome or elements thereof as genetic vector
C12N2740/12062	5	by genetic engineering
C12N2740/13022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/13043	5	viral genome or elements thereof as genetic vector
C12N2740/13062	5	by genetic engineering
C12N2740/14022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/14043	5	viral genome or elements thereof as genetic vector
C12N2740/14062	5	by genetic engineering
C12N2740/15022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/15043	5	viral genome or elements thereof as genetic vector
C12N2740/15062	5	by genetic engineering
C12N2740/16022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16043	5	viral genome or elements thereof as genetic vector
C12N2740/16062	5	by genetic engineering
C12N2740/16122	5	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16222	5	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16322	5	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/17022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/17043	5	viral genome or elements thereof as genetic vector
C12N2740/17062	5	by genetic engineering
C12N2750/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/00043	3	viral genome or elements thereof as genetic vector
C12N2750/00062	3	by genetic engineering
C12N2750/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/10043	4	viral genome or elements thereof as genetic vector
C12N2750/10062	4	by genetic engineering
C12N2750/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/12043	4	viral genome or elements thereof as genetic vector
C12N2750/12062	4	by genetic engineering
C12N2750/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14043	4	viral genome or elements thereof as genetic vector
C12N2750/14062	4	by genetic engineering
C12N2750/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14143	5	viral genome or elements thereof as genetic vector
C12N2750/14162	5	by genetic engineering
C12N2750/14222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14243	5	viral genome or elements thereof as genetic vector
C12N2750/14262	5	by genetic engineering
C12N2750/14322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14343	5	viral genome or elements thereof as genetic vector
C12N2750/14362	5	by genetic engineering
C12N2760/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/00043	3	viral genome or elements thereof as genetic vector
C12N2760/00062	3	by genetic engineering
C12N2760/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/10043	4	viral genome or elements thereof as genetic vector
C12N2760/10062	4	by genetic engineering
C12N2760/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/10143	5	viral genome or elements thereof as genetic vector
C12N2760/10162	5	by genetic engineering
C12N2760/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/12043	4	viral genome or elements thereof as genetic vector
C12N2760/12062	4	by genetic engineering
C12N2760/12122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/12143	5	viral genome or elements thereof as genetic vector
C12N2760/12162	5	by genetic engineering
C12N2760/12222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/12243	5	viral genome or elements thereof as genetic vector
C12N2760/12262	5	by genetic engineering
C12N2760/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/14043	4	viral genome or elements thereof as genetic vector
C12N2760/14062	4	by genetic engineering
C12N2760/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/14143	5	viral genome or elements thereof as genetic vector
C12N2760/14162	5	by genetic engineering
C12N2760/14222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/14243	5	viral genome or elements thereof as genetic vector
C12N2760/14262	5	by genetic engineering
C12N2760/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16043	4	viral genome or elements thereof as genetic vector
C12N2760/16062	4	by genetic engineering
C12N2760/16122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16143	5	viral genome or elements thereof as genetic vector
C12N2760/16162	5	by genetic engineering
C12N2760/16222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16243	5	viral genome or elements thereof as genetic vector
C12N2760/16262	5	by genetic engineering
C12N2760/16322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16343	5	viral genome or elements thereof as genetic vector
C12N2760/16362	5	by genetic engineering
C12N2760/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18043	4	viral genome or elements thereof as genetic vector
C12N2760/18062	4	by genetic engineering
C12N2760/18122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18143	5	viral genome or elements thereof as genetic vector
C12N2760/18162	5	by genetic engineering
C12N2760/18222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18243	5	viral genome or elements thereof as genetic vector
C12N2760/18262	5	by genetic engineering
C12N2760/18322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18343	5	viral genome or elements thereof as genetic vector
C12N2760/18362	5	by genetic engineering
C12N2760/18422	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18443	5	viral genome or elements thereof as genetic vector
C12N2760/18462	5	by genetic engineering
C12N2760/18522	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18543	5	viral genome or elements thereof as genetic vector
C12N2760/18562	5	by genetic engineering
C12N2760/18622	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18643	5	viral genome or elements thereof as genetic vector
C12N2760/18662	5	by genetic engineering
C12N2760/18722	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18743	5	viral genome or elements thereof as genetic vector
C12N2760/18762	5	by genetic engineering
C12N2760/18822	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18843	5	viral genome or elements thereof as genetic vector
C12N2760/18862	5	by genetic engineering
C12N2760/20022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/20043	4	viral genome or elements thereof as genetic vector
C12N2760/20062	4	by genetic engineering
C12N2760/20122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/20143	5	viral genome or elements thereof as genetic vector
C12N2760/20162	5	by genetic engineering
C12N2760/20222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/20243	5	viral genome or elements thereof as genetic vector
C12N2760/20262	5	by genetic engineering
C12N2770/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/00043	3	viral genome or elements thereof as genetic vector
C12N2770/00062	3	by genetic engineering
C12N2770/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/10043	4	viral genome or elements thereof as genetic vector
C12N2770/10062	4	by genetic engineering
C12N2770/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/12043	4	viral genome or elements thereof as genetic vector
C12N2770/12062	4	by genetic engineering
C12N2770/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/14043	4	viral genome or elements thereof as genetic vector
C12N2770/14062	4	by genetic engineering
C12N2770/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/16043	4	viral genome or elements thereof as genetic vector
C12N2770/16062	4	by genetic engineering
C12N2770/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/18043	4	viral genome or elements thereof as genetic vector
C12N2770/18062	4	by genetic engineering
C12N2770/20022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/20043	4	viral genome or elements thereof as genetic vector
C12N2770/20062	4	by genetic engineering
C12N2770/22022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/22043	4	viral genome or elements thereof as genetic vector
C12N2770/22062	4	by genetic engineering
C12N2770/24022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24043	4	viral genome or elements thereof as genetic vector
C12N2770/24062	4	by genetic engineering
C12N2770/24122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24143	5	viral genome or elements thereof as genetic vector
C12N2770/24162	5	by genetic engineering
C12N2770/24222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24243	5	viral genome or elements thereof as genetic vector
C12N2770/24262	5	by genetic engineering
C12N2770/24322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24343	5	viral genome or elements thereof as genetic vector
C12N2770/24362	5	by genetic engineering
C12N2770/26022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/26043	4	viral genome or elements thereof as genetic vector
C12N2770/26062	4	by genetic engineering
C12N2770/28022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/28043	4	viral genome or elements thereof as genetic vector
C12N2770/28062	4	by genetic engineering
C12N2770/28122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/28143	5	viral genome or elements thereof as genetic vector
C12N2770/28162	5	by genetic engineering
C12N2770/30022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/30043	4	viral genome or elements thereof as genetic vector
C12N2770/30062	4	by genetic engineering
C12N2770/32022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32043	4	viral genome or elements thereof as genetic vector
C12N2770/32062	4	by genetic engineering
C12N2770/32122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32143	5	viral genome or elements thereof as genetic vector
C12N2770/32162	5	by genetic engineering
C12N2770/32222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32243	5	viral genome or elements thereof as genetic vector
C12N2770/32262	5	by genetic engineering
C12N2770/32322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32343	5	viral genome or elements thereof as genetic vector
C12N2770/32362	5	by genetic engineering
C12N2770/32422	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32443	5	viral genome or elements thereof as genetic vector
C12N2770/32462	5	by genetic engineering
C12N2770/32522	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32543	5	viral genome or elements thereof as genetic vector
C12N2770/32562	5	by genetic engineering
C12N2770/32622	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32643	5	viral genome or elements thereof as genetic vector
C12N2770/32662	5	by genetic engineering
C12N2770/32722	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32743	5	viral genome or elements thereof as genetic vector
C12N2770/32762	5	by genetic engineering
C12N2770/34022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/34043	4	viral genome or elements thereof as genetic vector
C12N2770/34062	4	by genetic engineering
C12N2770/36022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/36043	4	viral genome or elements thereof as genetic vector
C12N2770/36062	4	by genetic engineering
C12N2770/36122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/36143	5	viral genome or elements thereof as genetic vector
C12N2770/36162	5	by genetic engineering
C12N2770/36222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/36243	5	viral genome or elements thereof as genetic vector
C12N2770/36262	5	by genetic engineering
C12N2770/38022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/38043	4	viral genome or elements thereof as genetic vector
C12N2770/38062	4	by genetic engineering
C12N2770/40022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/40043	4	viral genome or elements thereof as genetic vector
C12N2770/40062	4	by genetic engineering
C12N2780/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2780/00043	3	viral genome or elements thereof as genetic vector
C12N2780/00062	3	by genetic engineering
C12N2780/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2780/10043	4	viral genome or elements thereof as genetic vector
C12N2780/10062	4	by genetic engineering
C12N2790/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/00043	3	viral genome or elements thereof as genetic vector
C12N2790/00062	3	by genetic engineering
C12N2790/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/10043	4	viral genome or elements thereof as genetic vector
C12N2790/10062	4	by genetic engineering
C12N2790/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/12043	4	viral genome or elements thereof as genetic vector
C12N2790/12062	4	by genetic engineering
C12N2790/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/14043	4	viral genome or elements thereof as genetic vector
C12N2790/14062	4	by genetic engineering
C12N2792/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2792/00043	3	viral genome or elements thereof as genetic vector
C12N2792/00062	3	by genetic engineering
C12N2792/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2792/10043	4	viral genome or elements thereof as genetic vector
C12N2792/10062	4	by genetic engineering
C12N2792/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2792/12043	4	viral genome or elements thereof as genetic vector
C12N2792/12062	4	by genetic engineering
C12N2795/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/00043	3	viral genome or elements thereof as genetic vector
C12N2795/00062	3	by genetic engineering
C12N2795/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10043	4	viral genome or elements thereof as genetic vector
C12N2795/10062	4	by genetic engineering
C12N2795/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10143	5	viral genome or elements thereof as genetic vector
C12N2795/10162	5	by genetic engineering
C12N2795/10222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10243	5	viral genome or elements thereof as genetic vector
C12N2795/10262	5	by genetic engineering
C12N2795/10322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10343	5	viral genome or elements thereof as genetic vector
C12N2795/10362	5	by genetic engineering
C12N2795/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/12043	4	viral genome or elements thereof as genetic vector
C12N2795/12062	4	by genetic engineering
C12N2795/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14043	4	viral genome or elements thereof as genetic vector
C12N2795/14062	4	by genetic engineering
C12N2795/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14143	5	viral genome or elements thereof as genetic vector
C12N2795/14162	5	by genetic engineering
C12N2795/14222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14243	5	viral genome or elements thereof as genetic vector
C12N2795/14262	5	by genetic engineering
C12N2795/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/16043	4	viral genome or elements thereof as genetic vector
C12N2795/16062	4	by genetic engineering
C12N2795/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/18043	4	viral genome or elements thereof as genetic vector
C12N2795/18062	4	by genetic engineering
C12N2795/18122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/18143	5	viral genome or elements thereof as genetic vector
C12N2795/18162	5	by genetic engineering
C12N2830/20	1	transcription of more than one cistron
C12N2840/20	1	translation of more than one cistron
C12P		FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
C12Q1/6883	3	for diseases caused by alterations of genetic material
C12Q1/6897	2	involving reporter genes operably linked to promoters
C12Q2539/00	0	Reactions characterised by analysis of gene expression or genome comparison
C12Q2539/10	1	The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
C12Q2539/103	2	Serial analysis of gene expression [SAGE]
C12Q2565/20	1	Detection means characterised by being a gene reporter based analysis
C12Q2600/106	1	Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C40B40/08	3	Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
G01N2333/5753	3	Calcitonin gene related peptide
G05B23/0229	6	{knowledge based, e.g. expert systems; genetic algorithms}
G05B2219/32091	3	Algorithm, genetic algorithm, evolution strategy
G05B2219/32333	3	Use of genetic algorithm
G05B2219/33041	3	Structure optimization and learning of artificial neural network by genetic algorithm
G05B2219/35041	3	Genetic algorithm for selforganizing designs
G05B2219/40384	3	Optimize teached path by data acquisition followed by genetic algorithm
G05B2219/40473	3	Using genetic algorithm GA
G05B2219/42145	3	Coarse tune with genetic algorithm, fine with gradient descent, hill climbing
G05B2219/42147	3	Tune with genetic algorithm
G06F2111/06	1	Multi-objective optimisation, e.g. Pareto optimisation using simulated annealing [SA], ant colony algorithms or genetic algorithms [GA]
G06K7/1482	5	{using fuzzy logic or natural solvers, such as neural networks, genetic algorithms and simulated annealing}
G06K9/6229	4	{by using evolutionary computational techniques, e.g. genetic algorithms (genetic algorithms per se G06N3/126)}
G06N3/086	3	{using evolutionary programming, e.g. genetic algorithms}
G06N3/12	1	using genetic models
G06N3/126	2	{Genetic algorithms, i.e. information processing using digital simulations of the genetic system}
G10H2220/386	3	using genetic information [DNA] or unique characterizing features of individuals, e.g. fingerprints, iris, facial or vocal features
G10H2250/011	2	Genetic algorithms, i.e. using computational steps analogous to biological selection, recombination and mutation on an initial population of, e.g. sounds, pieces, melodies or loops to compose or otherwise generate, e.g. evolutionary music or sound synthesis
G10K2210/3029	3	Fuzzy logic; Genetic algorithms
G10L25/39	2	using genetic algorithms
G16B		BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
G16B5/00	0	ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B20/00	0	ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B20/40	1	Population genetics; Linkage disequilibrium
G16B25/00	0	ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
G16B25/10	1	Gene or protein expression profiling; Expression-ratio estimation or normalisation
G16B50/40	1	Encryption of genetic data
G16B50/50	1	Compression of genetic data
H01L21/108	5	Provision of discrete insulating layers, i.e. non-genetic barrier layers
H01L21/167	5	{Application of a non-genetic conductive layer}
Y10S530/808	1	Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
Y10S977/916	4	Gene therapy
A01H1/108	3	{involving amino acid content, e.g. synthetic storage proteins or altering amino acid biosynthesis}
A01K2207/10	1	Animals modified by protein administration, for non-therapeutic purpose
A01K2207/20	1	Animals treated with compounds which are neither proteins nor nucleic acids
A01K2267/01	1	Animal expressing industrially exogenous proteins
A01N63/50	1	Isolated enzymes; Isolated proteins (peptides A01N37/46)
A21D2/245	3	{Amino acids, nucleic acids}
A21D2/26	3	Proteins
A21D2/261	4	{Animal proteins}
A21D2/264	4	{Vegetable proteins}
A21D2/267	4	{Microbial proteins}
A21D2/268	4	{Hydrolysates from proteins (hydrolysis of proteins A23J3/30)}
A21D13/064	2	with modified protein content
A22C		PROCESSING MEAT, POULTRY, OR FISH (preserving A23B; obtaining protein compositions for foodstuffs A23J1/00; fish, meat or poultry preparations A23L; disintegrating, e.g. chopping meat, B02C18/00; preparation of proteins C07K1/00)
A22C13/0016	2	{based on proteins, e.g. collagen}
A23C		DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF (obtaining protein compositions for foodstuffs A23J1/00)
A23C7/04	1	Removing unwanted substances {other than lactose or milk proteins} from milk
A23C9/1315	3	{Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products}
A23C9/1322	3	{Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins}
A23C9/1422	3	{by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate}
A23C9/1465	3	{Chromatographic separation of protein or lactose fraction; Adsorption of protein or lactose fraction followed by elution}
A23C9/15	1	Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
A23C9/1512	2	{containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate}
A23C9/1516	2	{Enrichment or recombination of milk (excepted whey) with milk fat, cream of butter without using isolated or concentrated milk proteins}
A23C9/1526	2	{Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof}
A23C11/02	1	containing at least one non-milk component as source of fats or proteins (addition of non-milk fats or non-milk proteins in making cheese curd A23C19/055; whey or whey preparations containing non-milk components as source of fats or proteins A23C21/04)
A23C11/04	2	containing non-milk fats but no non-milk proteins (A23C11/08, A23C11/10 take precedence)
A23C11/06	2	containing non-milk proteins (A23C11/08, A23C11/10 take precedence)
A23C11/065	3	{Microbial proteins, inactivated yeast or animal proteins}
A23C11/08	2	containing caseinates but no other milk proteins nor milk fats
A23C11/10	2	containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
A23C11/103	3	{containing only proteins from pulses, oilseeds or nuts, e.g. nut milk}
A23C19/053	3	{Enrichment of milk with whey, whey components, substances recovered from separated whey, isolated or concentrated proteins from milk}
A23C19/054	3	{using additives other than acidifying agents, NaCl, CaCl2, dairy products, proteins, fats, enzymes or microorganisms}
A23C19/055	2	Addition of non-milk fats or non-milk proteins {, polyol fatty acid polyesters or mineral oils}
A23C19/0765	4	{Addition to the curd of additives other than acidifying agents, dairy products, proteins except gelatine, fats, enzymes, microorganisms, NaCl, CaCl2 or KCl; Foamed fresh cheese products}
A23C19/0917	3	{Addition, to cheese or curd, of whey, whey components, substances recovered from separated whey, isolated or concentrated proteins from milk}
A23C19/0921	3	{Addition, to cheese or curd, of minerals, including organic salts thereof, trace elements, amino acids, peptides, protein hydrolysates, nucleic acids, yeast extracts or autolysate, vitamins or derivatives of these compounds}
A23C19/093	3	Addition of non-milk fats or non-milk proteins
A23C20/005	1	{mainly containing proteins from pulses or oilseeds}
A23C20/02	1	containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates
A23C20/025	2	{mainly containing proteins from pulses or oilseeds}
A23C21/04	1	containing non-milk components as source of fats or proteins
A23G1/44	3	containing peptides or proteins (containing dairy products A23G1/46)
A23G3/44	3	containing peptides or proteins (containing dairy products A23G3/46)
A23G4/14	2	containing peptides or proteins (containing dairy products A23G4/16)
A23G9/38	2	containing peptides or proteins (characterised by the dairy products used A23G9/40)
A23G2200/10	1	containing amino-acids, proteins, e.g. gelatine, peptides, polypeptides
A23J		PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
A23J1/00	0	Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
A23J1/125	2	{by treatment involving enzymes or microorganisms (enzymatic hydrolysis of proteins A23J3/34)}
A23J1/148	2	{by treatment involving enzymes or microorganisms (enzymatic hydrolysis of proteins A23J3/34)}
A23J3/00	0	Working-up of proteins for foodstuffs
A23J3/04	1	Animal proteins
A23J3/08	2	Dairy proteins
A23J3/14	1	Vegetable proteins
A23J3/20	1	Proteins from microorganisms or unicellular algae
A23J3/225	2	{Texturised simulated foods with high protein content (synthetic caviar see A23L17/35)}
A23J3/341	4	{of animal proteins}
A23J3/343	5	{of dairy proteins}
A23J3/345	5	{of blood proteins}
A23J3/346	4	{of vegetable proteins}
A23J3/347	4	{of proteins from microorganisms or unicellular algae}
A23J3/348	4	{of proteins obtained from waste materials (A23J3/341, A23J3/346 take precedence)}
A23K10/16	2	Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions (A23K10/12 takes precedence)
A23K20/142	2	Amino acids; Derivatives thereof
A23K20/147	3	Polymeric derivatives, e.g. peptides or proteins
A23K50/15	2	containing substances which are metabolically converted to proteins, e.g. ammonium salts or urea
A23L2/66	2	Proteins
A23L9/22	2	{containing non-milk fats but no proteins other than milk proteins}
A23L9/24	2	{containing non-milk fats and non-milk proteins, e.g. eggs or soybeans}
A23L13/424	3	{Addition of non-meat animal protein material, e.g. blood, egg, dairy products, fish; Proteins from microorganisms, yeasts or fungi}
A23L13/426	3	{Addition of proteins, carbohydrates or fibrous material from vegetable origin other than sugars or sugar alcohols (A23L13/422 takes precedence)}
A23L13/428	3	{Addition of flavours, spices, colours, amino acids or their salts, peptides, vitamins, yeast extract or autolysate, nucleic acid or derivatives, organic acidifying agents or their salts or acidogens, sweeteners, e.g. sugars or sugar alcohols; Addition of alcohol-containing products}
A23L15/20	1	{Addition of proteins, e.g. hydrolysates, fats, carbohydrates, natural plant hydrocolloids; Addition of animal or vegetable substances containing proteins, fats, or carbohydrates}
A23L27/21	2	containing amino acids
A23L27/235	3	{containing also amino acids}
A23L27/31	2	{containing amino acids, nucleotides, peptides or derivatives}
A23L29/281	3	Proteins, e.g. gelatin or collagen
A23L33/17	2	Amino acids, peptides or proteins
A23L33/175	3	Amino acids
A23L33/18	3	Peptides; Protein hydrolysates
A23L33/185	3	Vegetable proteins
A23L33/19	3	Dairy proteins
A23L33/195	3	Proteins from microorganisms
A23V2200/13	2	Protein replacer
A23V2250/06	2	Amino acid
A23V2250/248	2	Di-Peptides sweeteners
A23V2250/54	1	Proteins
A23V2250/542	2	Animal Protein
A23V2250/5424	3	Dairy protein
A23V2250/54252	4	Whey protein
A23V2250/5428	3	Egg protein
A23V2250/543	3	Fish protein
A23V2250/546	2	Microbial protein
A23V2250/548	2	Vegetable protein
A23V2250/5482	3	Cereal protein
A23V2250/5484	3	Oat protein
A23V2250/5486	3	Wheat protein, gluten
A23V2250/5488	3	Soybean protein
A23V2250/55	2	Peptide, protein hydrolysate
A23V2300/06	1	Deamidation, e.g. deamidation of protein
A23V2300/08	1	Denaturation, e.g. denaturation of protein
A24B15/306	5	{one reactant being an amino acid or a protein, e.g. Maillard's reaction (A24B15/307 takes precedence)}
A47L15/0057	2	{Cleaning of machines parts, e.g. removal of deposits like lime scale or proteins from piping or tub}
A61F2002/2817	3	{Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]}
A61F13/00012	3	{being made of natural material, e.g. cellulose-, protein-, collagen-based}
A61F2310/00365	2	Proteins; Polypeptides; Degradation products thereof
A61F2310/00976	2	Coating or prosthesis-covering structure made of proteins or of polypeptides, e.g. of bone morphogenic proteins BMP or of transforming growth factors TGF
A61K8/64	3	Proteins; Peptides; Derivatives or degradation products thereof
A61K8/645	4	{Proteins of vegetable origin; Derivatives or degradation products thereof}
A61K9/1275	3	{Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof}
A61K9/1658	5	{Proteins, e.g. albumin, gelatin}
A61K9/2045	5	{Polyamides; Polyaminoacids, e.g. polylysine}
A61K9/2063	4	{Proteins, e.g. gelatin}
A61K9/2873	5	{Proteins, e.g. gelatin}
A61K9/4825	3	{Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
A61K9/5052	5	{Proteins, e.g. albumin}
A61K9/5169	6	{Proteins, e.g. albumin, gelatin}
A61K31/198	5	Alpha-aminoacids, e.g. alanine, edetic acids [EDTA], (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual aminoacids A61K38/00)
A61K31/223	4	of alpha-aminoacids
A61K35/583	3	Snakes; Lizards, e.g. chameleons (therapeutic use of a snake venom protein A61K38/00)
A61K35/74	2	Bacteria (therapeutic use of a bacterial protein A61K38/00)
A61K38/00	0	Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
A61K38/01	1	Hydrolysed proteins; Derivatives thereof
A61K38/014	3	{from connective tissue peptides, e.g. gelatin, collagen}
A61K38/02	1	Peptides of undefined number of amino acids; Derivatives thereof
A61K38/03	1	Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
A61K38/04	1	Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005}; gastrins {A61K38/2207} somatostatins A61K38/31, melanotropins A61K38/34; {protease inhibitors A61K38/55})
A61K38/043	2	{Kallidins; Bradykinins; Related peptides}
A61K38/046	2	{Tachykinins, e.g. eledoisins, substance P; Related peptides}
A61K38/08	2	Peptides having 5 to 11 amino acids {(A61K38/043-A61K38/046 take precedence)}
A61K38/09	3	Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
A61K38/095	3	Oxytocins; Vasopressins; Related peptides
A61K38/10	2	Peptides having 12 to 20 amino acids {(A61K38/043-A61K38/046 take precedence)}
A61K38/105	3	{Bombesin; Related peptides}
A61K38/12	2	Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043-A61K38/046 take precedence)}
A61K38/14	2	Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
A61K38/16	1	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
A61K38/1716	5	{Amyloid plaque core protein}
A61K38/1719	5	{Muscle proteins, e.g. myosin or actin}
A61K38/1725	5	{Complement proteins, e.g. anaphylatoxin, C3a or C5a}
A61K38/1729	5	{Cationic antimicrobial peptides, e.g. defensins}
A61K38/1738	5	{Calcium binding proteins, e.g. calmodulin}
A61K38/1745	5	{C-reactive proteins}
A61K38/1751	5	{Bactericidal/permeability-increasing protein [BPI]}
A61K38/1754	5	{Insulin-like growth factor binding proteins}
A61K38/1761	5	{Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2}
A61K38/2242	4	{Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin}
A61K38/225	4	{Calcitonin gene related peptide}
A61K38/2278	4	{Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
A61K38/2292	4	{Thymosin; Related peptides}
A61K38/29	4	Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
A61K38/30	4	Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
A61K38/39	3	Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
A61K38/395	3	{Alveolar surfactant peptides; Pulmonary surfactant peptides}
A61K38/41	2	Porphyrin- or corrin-ring-containing peptides
A61K38/48	4	acting on peptide bonds (3.4)
A61K38/4866	6	{Protein C (3.4.21.69)}
A61K38/50	4	acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K39/001149	4	{Cell cycle regulated proteins, e.g. cyclin, CDC, CDK, INK-CCR}
A61K39/00115	4	{Apoptosis related proteins, e.g. survivin, livin}
A61K39/001176	3	{Heat shock proteins}
A61K39/001181	4	{Alpha-feto protein}
A61K39/001196	3	{Fusion proteins originating from gene translocation in cancer cells}
A61K2039/5156	3	{expressing foreign proteins}
A61K2039/523	3	{expressing foreign proteins}
A61K2039/5256	3	{expressing foreign proteins}
A61K2039/55516	3	{Proteins; Peptides}
A61K2039/6031	2	{Proteins}
A61K2039/6043	3	{Heat shock proteins}
A61K2039/6062	3	{Muramyl peptides}
A61K2039/6068	3	{Other bacterial proteins, e.g. OMP}
A61K2039/6075	3	{Viral proteins}
A61K2039/645	2	{Dendrimers; Multiple antigen peptides}
A61K47/18	3	Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K47/183	4	{Amino acids, e.g. glycine, EDTA or aspartame}
A61K47/34	2	Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
A61K47/42	2	Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
A61K47/542	4	{Carboxylic acids, e.g. a fatty acid or an amino acid}
A61K47/547	4	{Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
A61K47/555	4	{pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
A61K47/595	5	{Polyamides, e.g. nylon (polyamino acids A61K47/62)}
A61K47/62	3	the modifying agent being a protein, peptide or polyamino acid
A61K47/64	4	Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
A61K47/641	5	{Branched, dendritic or hypercomb peptides}
A61K47/642	5	{the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}
A61K47/6425	5	{the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
A61K47/6435	5	{the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin}
A61K47/645	5	{Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
A61K47/6455	6	{Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
A61K47/646	5	{the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
A61K47/66	4	the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61K47/6811	6	{the drug being a protein or peptide, e.g. transferrin or bleomycin}
A61K47/6825	9	{Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin}
A61K47/6917	4	{the form being a lipoprotein vesicle, e.g. HDL or LDL proteins}
A61K49/0045	5	{the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo}
A61K49/0047	6	{Green fluorescent protein [GFP]}
A61K49/0056	5	{Peptides, proteins, polyamino acids}
A61K49/008	5	{lipoprotein vesicle, e.g. HDL or LDL proteins}
A61K49/14	4	Peptides, e.g. proteins
A61K49/143	5	{the protein being an albumin, e.g. HSA, BSA, ovalbumin}
A61K49/146	5	{the peptide being a polyamino acid, e.g. poly-lysine}
A61K49/1851	7	{having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule (peptide or protein A61K49/1866; polyamino acid A61K49/1872; antibody A61K49/1875)}
A61K49/1866	7	{the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid}
A61K49/1869	8	{coated or functionalised with a protein being an albumin, e.g. HSA, BSA, ovalbumin}
A61K49/1872	8	{coated or functionalised with a polyamino acid, e.g. polylysine, polyglutamic acid}
A61K51/0402	3	{carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}
A61K51/0406	4	{Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines}
A61K51/06	3	Macromolecular compounds {, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules (peptides, proteins, polyamino acids A61K51/08; antibodies A61K51/10)}
A61K51/08	3	Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
A61K51/081	4	{the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin}
A61K51/082	4	{the peptide being a RGD-containing peptide}
A61K51/083	4	{the peptide being octreotide or a somatostatin-receptor-binding peptide}
A61K51/084	4	{the peptide being oxytocin}
A61K51/085	4	{the peptide being neurotensin}
A61K51/086	4	{the peptide being alphaMSH, alpha melanocyte stimulating hormone}
A61K51/087	4	{the peptide being an annexin, e.g. annexin V}
A61K51/088	4	{conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
A61K51/1224	3	{Lipoprotein vesicles, e.g. HDL and LDL proteins}
A61L15/32	3	Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)}
A61L24/10	2	Polypeptides; Proteins {(A61L24/043 takes precedence)}
A61L24/108	3	{Specific proteins or polypeptides not covered by groups A61L24/102-A61L24/106}
A61L26/0028	2	{Polypeptides; Proteins; Degradation products thereof}
A61L26/0047	3	{Specific proteins or polypeptides not covered by groups A61L26/0033-A61L26/0042}
A61L27/22	2	Polypeptides or derivatives thereof {, e.g. degradation products}
A61L27/227	3	{Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
A61L27/3683	2	{subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
A61L28/0023	2	{Polypeptides; Proteins; Degradation products thereof}
A61L29/044	2	{Proteins; Polypeptides; Degradation products thereof}
A61L29/048	3	{Other specific proteins or polypeptides not covered by A61L29/045-A61L29/047}
A61L31/043	2	{Proteins; Polypeptides; Degradation products thereof}
A61L31/047	3	{Other specific proteins or polypeptides not covered by A61L31/044-A61L31/046}
A61L33/0041	3	{characterised by the choice of an antithrombatic agent other than heparin (heparinod A61L33/08; polypeptides A61L33/12)}
A61L33/12	2	Polypeptides, proteins or derivatives thereof {, e.g. degradation products thereof}
A61L33/128	3	{Other specific proteins or polypeptides not covered by A61L33/122-A61L33/126}
A61L2300/214	3	Amino acids
A61L2300/25	2	Peptides having up to 20 amino acids in a defined sequence
A61L2300/252	2	Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
A61M1/1676	4	{containing proteins, e.g. albumin}
A61M2202/0445	3	Proteins (immunoglobulin A61M2202/0417; beta-2-microglobulin A61M2202/0421; thrombin A61M2202/0425; haemoglobin A61M2202/0433)
A61M2202/07	1	Proteins
A62D1/0078	2	{containing proteins or protein derivatives}
B01D15/3809	5	{of the antigen-antibody type, e.g. protein A, G, L chromatography}
B01D15/3819	5	{of the nucleic acid-nucleic acid binding protein type}
B01D2252/20494	3	Amino acids, their salts or derivatives
B01F23/062	2	{Mixing ingredients in very small quantity, adding microingredients or microconcentration, e.g. adding vitamins, minerals, proteins, enzymes, hormones, antibiotics or worm medicines}
B01J19/0046	1	{Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays (synthesis methods per se C40B50/00)}
B01J20/3274	7	{Proteins, nucleic acids, polysaccharides, antibodies or antigens}
B01J31/062	4	{Polymeric amino acids}
B01J47/014	1	in which the adsorbent properties of the ion-exchanger are involved, e.g. recovery of proteins or other high-molecular compounds
B01J2219/00725	4	Peptides
B01J2219/00729	4	Peptide nucleic acids [PNA]
B01J2220/4856	4	Proteins, DNA
B01J2531/0275	3	derived from amino acids
B29K2089/00	0	Use of proteins, e.g. casein, gelatine or derivatives thereof, as moulding material
B29K2289/00	0	Use of proteins, e.g. casein, gelatine or derivatives thereof, as reinforcement
B29K2489/00	0	Use of proteins, e.g. casein or gelatine or derivatives thereof, as filler
B29K2689/00	0	Use of proteins, e.g. casein, gelatine or derivatives thereof, for preformed parts, e.g. for inserts
B29K2889/00	0	Use of proteins, e.g. casein or gelatine or derivatives thereof, as mould material
B41M5/5236	3	{characterised by the use of natural gums, of proteins, e.g. gelatins, or of macromolecular carbohydrates, e.g. cellulose}
B82Y5/00	0	Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y15/00	0	Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
C04B24/14	2	Peptides; Proteins; Derivatives thereof
C04B26/026	2	{Proteins or derivatives thereof}
C04B41/4807	4	{Proteins or derivatives thereof}
C07B59/008	1	{Peptides; Proteins}
C07C237/12	3	having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups (peptides C07K)
C07C237/22	2	having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
C07D457/00	0	Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: [IMAGE cpc-sch-C07D-0988.gif] , e.g. lysergic acid (compounds of the cyclic peptide type derived from ergotamane C07D519/02)
C07D519/02	1	Ergot alkaloids of the cyclic peptide type
C07K		PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
C07K1/00	0	General methods for the preparation of peptides {, i.e. processes for the organic chemical preparation of peptides or proteins of any length}
C07K1/003	1	{by transforming the C-terminal amino acid to amides}
C07K1/006	1	{of peptides containing derivatised side chain amino acids}
C07K1/047	2	{Simultaneous synthesis of different peptide species; Peptide libraries}
C07K1/107	1	by chemical modification of precursor peptides
C07K1/1075	3	{by covalent attachment of amino acids or peptide residues}
C07K1/1077	3	{by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
C07K1/13	1	Labelling of peptides
C07K2/00	0	Peptides of undefined number of amino acids; Derivatives thereof
C07K4/00	0	Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
C07K5/00	0	Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
C07K5/02	1	containing at least one abnormal peptide link
C07K5/0202	2	{containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids}
C07K5/0207	2	{containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids}
C07K5/021	2	{containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06-C07K5/10, according to the moiety having normal peptide bonds}
C07K5/0212	2	{containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides}
C07K5/0215	2	{containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu}
C07K5/0222	3	{with the first amino acid being heterocyclic, e.g. Pro, Trp}
C07K5/0227	2	{containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06-C07K5/10}
C07K5/04	1	containing only normal peptide links
C07K5/06008	3	{with the first amino acid being neutral}
C07K5/06043	6	{Leu-amino acid}
C07K5/06052	6	{Val-amino acid}
C07K5/06069	6	{Ser-amino acid}
C07K5/06086	3	{with the first amino acid being basic}
C07K5/06095	4	{Arg-amino acid}
C07K5/06104	3	{with the first amino acid being acidic}
C07K5/06113	4	{Asp- or Asn-amino acid}
C07K5/06121	5	{the second amino acid being aromatic or cycloaliphatic}
C07K5/06139	3	{with the first amino acid being heterocyclic}
C07K5/06147	4	{and His-amino acid; Derivatives thereof}
C07K5/06156	4	{and Trp-amino acid; Derivatives thereof}
C07K5/06165	4	{and Pro-amino acid; Derivatives thereof}
C07K5/06173	4	{and Glp-amino acid; Derivatives thereof}
C07K5/0802	3	{with the first amino acid being neutral}
C07K5/0815	3	{with the first amino acid being basic}
C07K5/0817	4	{the first amino acid being Arg}
C07K5/0819	3	{with the first amino acid being acidic}
C07K5/0821	3	{with the first amino acid being heterocyclic, e.g. His, Pro, Trp}
C07K5/0823	4	{and Pro-amino acid; Derivatives thereof}
C07K5/0825	4	{and Glp-amino acid; Derivatives thereof}
C07K5/1002	3	{with the first amino acid being neutral}
C07K5/1019	3	{with the first amino acid being basic}
C07K5/1021	3	{with the first amino acid being acidic}
C07K5/1024	3	{with the first amino acid being heterocyclic}
C07K5/12	2	Cyclic peptides {with only normal peptide bonds in the ring}
C07K7/00	0	Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
C07K7/02	1	Linear peptides containing at least one abnormal peptide link
C07K7/04	1	Linear peptides containing only normal peptide links
C07K7/06	2	having 5 to 11 amino acids
C07K7/067	3	{Hemoregulatory peptides based on sequence Glp-Glu-Asp-Cys-Lys}
C07K7/08	2	having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
C07K7/086	3	{Bombesin; Related peptides (having more than 20 amino acids C07K14/57572)}
C07K7/14	2	Angiotensins: Related peptides
C07K7/16	2	Oxytocins; Vasopressins; Related peptides
C07K7/18	2	Kallidins; Bradykinins; Related peptides
C07K7/22	2	{Tachykinins, e.g.} Eledoisins {, Substance P}; Related peptides
C07K7/23	2	Luteinising hormone-releasing hormone [LHRH]; Related peptides
C07K7/28	2	Gramicidins A, B, D; Related peptides
C07K7/50	1	Cyclic peptides containing at least one abnormal peptide link
C07K7/52	2	with only normal peptide links in the ring
C07K7/54	2	with at least one abnormal peptide link in the ring
C07K7/58	4	Bacitracins; Related peptides
C07K7/62	4	Polymyxins; Related peptides
C07K7/64	1	Cyclic peptides containing only normal peptide links
C07K7/645	2	{Cyclosporins; Related peptides}
C07K7/66	2	Gramicidins S, C; Tyrocidins A, B, C; Related peptides
C07K9/00	0	Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
C07K9/001	1	{the peptide sequence having less than 12 amino acids and not being part of a ring structure}
C07K9/003	2	{Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin}
C07K9/006	1	{the peptide sequence being part of a ring structure}
C07K11/00	0	Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
C07K14/00	0	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K14/003	2	{Peptide-nucleic acids (PNAs)}
C07K14/163	6	{Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx}
C07K14/325	3	Bacillus thuringiensis crystal protein (delta-endotoxin)
C07K14/4706	7	{Guanosine triphosphatase activating protein, GAP}
C07K14/4711	5	{Alzheimer's disease; Amyloid plaque core protein}
C07K14/4715	5	{Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein}
C07K14/4716	5	{Muscle proteins, e.g. myosin, actin}
C07K14/4718	5	{Cytokine-induced proteins}
C07K14/472	5	{Complement proteins, e.g. anaphylatoxin, C3a, C5a}
C07K14/4722	5	{G-proteins}
C07K14/4723	5	{Cationic antimicrobial peptides, e.g. defensins}
C07K14/4728	5	{Calcium binding proteins, e.g. calmodulin}
C07K14/4733	5	{Acute pancreatitis-associated protein}
C07K14/4736	5	{Retinoblastoma protein}
C07K14/4737	5	{C-reactive protein}
C07K14/4738	5	{Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
C07K14/474	5	{Pancreatic thread protein; Reg protein}
C07K14/4742	5	{Bactericidal/Permeability-increasing protein [BPI]}
C07K14/4743	5	{Insulin-like growth factor binding protein}
C07K14/4747	5	{Apoptosis related proteins}
C07K14/57527	3	{Calcitonin gene related peptide}
C07K14/57563	3	{Vasoactive intestinal peptide [VIP]; Related peptides}
C07K14/57572	3	{Gastrin releasing peptide (bombesin C07K7/086)}
C07K14/57581	3	{Thymosin; Related peptides}
C07K14/58	3	Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
C07K14/582	4	{at least 1 amino acid in D-form}
C07K14/5855	4	{at least 1 amino acid in D-form}
C07K14/592	4	{at least 1 amino acid in D-form}
C07K14/5955	4	{at least 1 amino acid in D-form}
C07K14/622	4	{at least 1 amino acid in D-form}
C07K14/635	3	Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
C07K14/6555	4	{at least 1 amino acid in D-form}
C07K14/662	4	{at least 1 amino acid in D-form}
C07K14/672	4	{with at least 1 amino acid in D-form}
C07K14/6755	4	{with at least 1 amino acid in D-form}
C07K14/6955	4	{with at least 1 amino acid in D-form}
C07K14/702	4	{with at least 1 amino acid in D-form}
C07K14/723	4	{G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor}
C07K14/78	2	Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
C07K14/785	2	Alveolar surfactant peptides; Pulmonary surfactant peptides
C07K14/795	1	Porphyrin- or corrin-ring-containing peptides
C07K16/1072	5	{Regulatory proteins, e.g. tat, rev, vpt}
C07K16/38	1	against protease inhibitors of peptide structure
C07K16/44	1	against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
C07K16/46	1	Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
C07K17/00	0	Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof
C07K17/02	1	Peptides being immobilised on, or in, an organic carrier
C07K17/14	1	Peptides being immobilised on, or in, an inorganic carrier
C07K19/00	0	Hybrid peptides
C07K2299/00	0	Coordinates from 3D structures of peptides, e.g. proteins or enzymes
C07K2317/34	2	Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K2318/10	1	Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
C07K2319/00	0	Fusion polypeptide
C07K2319/034	2	containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
C07K2319/035	2	containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
C07K2319/20	1	containing a tag with affinity for a non-protein ligand
C07K2319/24	2	containing a MBP (maltose binding protein)-tag
C07K2319/30	1	Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
C07K2319/60	1	containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
C07K2319/70	1	containing domain for protein-protein interaction
C07K2319/705	2	containing a protein-A fusion
C07K2319/735	2	containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
C07K2319/75	3	containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
C07K2319/92	2	containing an intein ("protein splicing")domain
C08B37/0081	4	{Reaction with amino acids, peptides, or proteins}
C08G18/6446	6	{Proteins and derivatives thereof}
C08G69/36	2	derived from amino acids, polyamines and polycarboxylic acids
C08H1/00	0	Macromolecular products derived from proteins (food proteins A23; glue, gelatine C09H)
C08H1/02	1	Protein-aldehyde condensates
C08J2389/00	0	Characterised by the use of proteins; Derivatives thereof
C08J2489/00	0	Characterised by the use of proteins; Derivatives thereof
C08L89/00	0	Compositions of proteins; Compositions of derivatives thereof (foodstuff preparations A23J3/00)
C09D11/04	2	based on proteins
C09D189/00	0	Coating compositions based on proteins; Coating compositions based on derivatives thereof (foodstuff preparations A23J3/00)
C09J189/00	0	Adhesives based on proteins; Adhesives based on derivatives thereof
C09J2489/00	0	Presence of protein
C09K19/3871	6	{containing amino acid derivatives}
C09K19/389	4	{Polypeptides}
C09K23/28	1	Aminocarboxylic acids (proteins and protein hydrolysates C09K23/30)
C09K23/30	1	Proteins; Protein hydrolysates
C09K2200/0482	3	Peptides, proteins or derivatives thereof
C11D1/32	2	Protein hydrolysates; Fatty acid condensates thereof
C11D7/3245	3	{Aminoacids}
C11D9/40	3	Proteins
C12N5/005	2	{Protein-free medium}
C12N9/0024	5	{D-Amino acid oxidase (1.4.3.3)}
C12N9/0038	4	{with a heme protein as acceptor (1.6.2)}
C12N9/0077	3	{with a reduced iron-sulfur protein as one donor (1.14.15)}
C12N9/0079	4	{Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
C12N9/0095	2	{acting on iron-sulfur proteins as donor (1.18)}
C12N9/1044	4	{Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}
C12N9/1205	3	{Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
C12N9/48	2	acting on peptide bonds (3.4)
C12N9/6464	7	{Protein C (3.4.21.69)}
C12N9/78	2	acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C12N15/1044	4	{Preparation or screening of libraries displayed on scaffold proteins}
C12N15/1055	4	{Protein x Protein interaction, e.g. two hybrid selection}
C12N15/1062	4	{mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
C12N15/1068	4	{Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
C12N15/1138	4	{against receptors or cell surface proteins}
C12N15/62	3	DNA sequences coding for fusion proteins
C12N15/8212	8	{Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid}
C12N15/8221	6	{Transit peptides}
C12N15/8251	8	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}
C12N2015/8518	6	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
C12N2310/153	3	with the aid of a protein, e.g. recombinase
C12N2310/3181	4	Peptide nucleic acid, PNA
C12N2310/3513	4	Protein; Peptide
C12N2500/32	2	Amino acids
C12N2500/33	3	other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
C12N2500/95	2	Protein-free medium and culture conditions
C12N2501/054	2	Muramyle peptides
C12N2501/07	1	Heat shock proteins
C12N2501/155	2	Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
C12N2501/335	2	Glucagon; Glucagon-like peptide [GLP]; Exendin
C12N2501/34	2	Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
C12N2501/35	2	Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
C12N2501/405	2	Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
C12N2501/41	2	Hedgehog proteins; Cyclopamine (inhibitor)
C12N2501/835	2	Neuropeptide Y [NPY]; Peptide YY [PYY]
C12N2501/84	2	Excitatory amino acids
C12N2501/998	1	Proteins not provided for elsewhere
C12N2533/50	1	Proteins
C12N2710/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/10134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/10222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/10234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/10322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/10334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/14033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/14034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/14133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/14134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16422	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16433	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16434	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16522	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16533	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16622	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16633	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16634	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16722	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16733	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16734	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/18033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/18034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/20022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/20033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/20034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/22022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/22033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/22034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/24022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/24034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/24122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/24134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/24222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/24234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2720/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2720/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2720/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2720/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2720/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2720/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2720/12122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2720/12134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2720/12222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2720/12234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2720/12322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2720/12333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2720/12334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2730/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2730/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2730/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2730/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2730/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/10133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2730/10134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/11022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/11033	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/11034	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/12022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/12033	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/12034	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/13022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/13033	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/13034	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/14022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/14033	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/14034	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/15022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/15033	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/15034	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/16022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16033	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/16034	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/16122	5	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16134	5	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/16222	5	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16234	5	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/16311	4	concerning HIV regulatory proteins
C12N2740/16322	5	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16334	5	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/17022	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/17033	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2740/17034	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/14034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/14134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/14222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/14234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/14322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/14334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/10133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/10134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/12122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/12133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/12134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/12222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/12233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/12234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/14033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/14034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/14133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/14134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/14233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/14234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/16034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/16134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/16234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/16334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18422	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18433	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18434	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18522	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18533	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18534	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18622	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18633	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18634	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18722	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18733	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18734	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18822	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18833	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18834	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/20022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/20033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/20034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/20122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/20133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/20134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/20222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/20233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/20234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/14033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/14034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/16033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/16034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/18033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/18034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/20022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/20033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/20034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/22022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/22033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/22034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/24022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/24034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/24122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/24134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/24222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/24234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/24322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/24333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/24334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/26022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/26033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/26034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/28022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/28033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/28034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/28122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/28133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/28134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/30022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/30033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/30034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32422	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32433	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32434	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32522	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32533	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32534	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32622	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32633	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32634	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32722	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32733	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/32734	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/34022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/34033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/34034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/36022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/36033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/36034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/36122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/36133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/36134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/36222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/36233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/36234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/38022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/38033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/38034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/40022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/40033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/40034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2780/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2780/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2780/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2780/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2780/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2780/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2790/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2790/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2790/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2790/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2790/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2790/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2790/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2790/14033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2790/14034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2792/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2792/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2792/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2792/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2792/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2792/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2792/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2792/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2792/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/00022	2	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/00033	2	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/00034	2	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/10022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/10034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/10122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/10134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/10222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/10234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/10322	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10333	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/10334	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/12022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/12033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/12034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/14022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/14034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/14122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/14134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/14222	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14233	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/14234	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/16022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/16033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/16034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/18022	3	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/18033	3	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/18034	3	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/18122	4	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/18133	4	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/18134	4	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2810/40	1	Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
C12N2810/405	2	Vectors comprising RGD peptide
C12N2810/50	1	Vectors comprising as targeting moiety peptide derived from defined protein
C12N2999/005	1	Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
C12P		FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
C12P7/34	4	produced from substrate containing protein as nitrogen source
C12P13/005	1	{Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids}
C12P13/02	1	Amides, e.g. chloramphenicol {or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes (peptides C12P21/00 or C07K)}
C12P13/04	1	Alpha- or beta- amino acids {(other amino acids C12P13/005)}
C12P21/00	0	Preparation of peptides or proteins (single cell protein C12N1/00)
C12P21/02	1	having a known sequence of two or more amino acids, e.g. glutathione
C12P21/06	1	produced by the hydrolysis of a peptide bond, e.g. hydrolysate products (preparing foodstuffs by protein hydrolysis A23J3/00)
C12Q2521/514	2	Mismatch repair protein
C12Q2522/00	0	Reaction characterised by the use of non-enzymatic proteins
C12Q2522/10	1	Nucleic acid binding proteins
C12Q2522/101	2	Single or double stranded nucleic acid binding proteins
C12Q2525/107	2	incorporating a peptide nucleic acid
C12Q2525/203	2	incorporating a composite nucleic acid containing a polypeptide sequence other than PNA
C12Q2561/127	1	Protein truncation assay
C12Q2563/125	1	the label being enzymatic, i.e. proteins, and non proteins, such as nucleic acid with enzymatic activity
C12Q2565/531	2	characterised by the capture moiety being a protein for target oligonucleotides
C12Y101/011	2	3-Oxoacyl-[acyl-carrier-protein] reductase (1.1.1.100)
C12Y101/01212	2	3-Oxoacyl-[acyl-carrier-protein] reductase (NADH) (1.1.1.212)
C12Y101/09	1	with a copper protein as acceptor (1.1.9)
C12Y102/0108	2	Long-chain acyl-[acyl-carrier-protein] reductase (1.2.1.80)
C12Y102/07	1	with an iron-sulfur protein as acceptor (1.2.7)
C12Y103/01009	2	Enoyl-[acyl-carrier-protein] reductase (NADH) (1.3.1.9)
C12Y103/0101	2	Enoyl-[acyl-carrier-protein] reductase (NADPH, B-specific)(1.3.1.10)
C12Y103/01039	2	Enoyl-[acyl-carrier-protein] reductase (NADPH, A-specific)(1.3.1.39)
C12Y103/07	1	with an iron-sulfur protein as acceptor (1.3.7)
C12Y104/03013	2	Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
C12Y104/05001	2	D-Amino acid dehydrogenase (quinone) (1.4.5.1)
C12Y104/07	1	with an iron-sulfur protein as acceptor (1.4.7)
C12Y104/09	1	with a copper protein as acceptor (1.4.9)
C12Y105/07	1	with an iron-sulfur protein as acceptor (1.5.7)
C12Y106/02	1	with a heme protein as acceptor (1.6.2)
C12Y107/07	1	with an iron-sulfur protein as acceptor (1.7.7)
C12Y108/01008	2	Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
C12Y108/04002	2	Protein-disulfide reductase (glutathione) (1.8.4.2), i.e. BdbC or BdbD
C12Y108/04011	2	Peptide-methionine (S)-S-oxide reductase (1.8.4.11)
C12Y108/04012	2	Peptide-methionine (R)-S-oxide reductase (1.8.4.12)
C12Y108/07	1	with an iron-sulfur protein as acceptor (1.8.7)
C12Y110/09	1	with a copper protein as acceptor (1.10.9)
C12Y112/07	1	with an iron-sulfur protein as acceptor (1.12.7)
C12Y113/11026	2	Peptide-tryptophan 2,3-dioxygenase (1.13.11.26)
C12Y114/11016	2	Peptide-aspartate beta-dioxygenase (1.14.11.16), i.e. aspartyl (asparaginyl) beta-hydroxylase
C12Y114/14013	2	4-(L-Gamma-glutamylamino)butanoyl-[BtrI acyl-carrier protein] monooxygenase (1.14.14.13)
C12Y114/15	1	with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen (1.14.15)
C12Y114/19002	2	Acyl-[acyl-carrier-protein] desaturase (1.14.19.2)
C12Y116/09	1	with a copper protein as acceptor (1.16.9)
C12Y117/07	1	with an iron-sulfur protein as acceptor (1.17.7)
C12Y118/00	0	Oxidoreductases acting on iron-sulfur proteins as donors (1.18)
C12Y120/09	1	with a copper protein as acceptor (1.20.9)
C12Y201/01023	2	Protein-arginine N-methyltransferase (2.1.1.23) (C12Y201/01124 - C12Y201/01126 take precedence)
C12Y201/01024	2	Protein-gamma-glutamate O-methyltransferase (2.1.1.24) (C12Y201/01077, C12Y201/0108, C12Y201/011 take precedence)
C12Y201/01063	2	Methylated-DNA-[protein]-cysteine S-methyltransferase (2.1.1.63), i.e. O6-methylguanine-DNA methyltransferase
C12Y201/01077	2	Protein-L-isoaspartate(D-aspartate) O-methyltransferase (2.1.1.77)
C12Y201/0108	2	Protein-glutamate O-methyltransferase (2.1.1.80)
C12Y201/01085	2	Protein-histidine N-methyltransferase (2.1.1.85)
C12Y201/0109	2	Methanolcorrinoid protein Co-methyltransferase (2.1.1.90)
C12Y201/011	2	Protein-S-isoprenylcysteine O-methyltransferase (2.1.1.100)
C12Y201/01126	2	[Myelin basic protein]-arginine N-methyltransferase (2.1.1.126)
C12Y201/01233	2	[Phosphatase 2A protein]-leucine-carboxy methyltransferase (2.1.1.233)
C12Y201/01244	2	Protein N-terminal methyltransferase (2.1.1.244)
C12Y201/01245	2	5-Methyltetrahydrosarcinapterin:corrinoid/iron-sulfur protein Co-methyltransferase (2.1.1.245)
C12Y201/01246	2	[Methyl-Co(III) methanol-specific corrinoid protein]:coenzyme M methyltransferase (2.1.1.246)
C12Y201/01247	2	[Methyl-Co(III) methylamine-specific corrinoid protein]:coenzyme M methyltransferase (2.1.1.247)
C12Y201/01248	2	Methylaminecorrinoid protein Co-methyltransferase (2.1.1.248)
C12Y201/01249	2	Dimethylaminecorrinoid protein Co-methyltransferase (2.1.1.249)
C12Y201/0125	2	Trimethylaminecorrinoid protein Co-methyltransferase (2.1.1.250)
C12Y201/01252	2	Tetramethylammoniumcorrinoid protein Co-methyltransferase (2.1.1.252)
C12Y201/01253	2	[Methyl-Co(III) tetramethylammonium-specific corrinoid protein]:coenzyme M methyltransferase (2.1.1.253)
C12Y201/01258	2	5-Methyltetrahydrofolate:corrinoid/iron-sulfur protein Co-methyltransferase (2.1.1.258)
C12Y201/0301	2	Malonyl-S-ACP:biotin-protein carboxyltransferase (2.1.3.10)
C12Y203/01038	2	[Acyl-carrier-protein] S-acetyltransferase (2.3.1.38)
C12Y203/01039	2	[Acyl-carrier-protein] S-malonyltransferase (2.3.1.39)
C12Y203/0104	2	Acyl-[acyl-carrier-protein]-phospholipid O-acyltransferase (2.3.1.40)
C12Y203/01041	2	Beta-ketoacyl-acyl-carrier-protein synthase I (2.3.1.41)
C12Y203/01065	2	Bile acid-CoA:amino acid N-acyltransferase (2.3.1.65)
C12Y203/01088	2	Peptide alpha-N-acetyltransferase (2.3.1.88)
C12Y203/01128	2	Ribosomal-protein-alanine N-acetyltransferase (2.3.1.128)
C12Y203/01129	2	Acyl-[acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase (2.3.1.129)
C12Y203/01179	2	Beta-ketoacyl-acyl-carrier-protein synthase II (2.3.1.179)
C12Y203/0118	2	Beta-ketoacyl-acyl-carrier-protein synthase III (2.3.1.180)
C12Y203/01204	2	Octanoyl-[GcvH]:protein N-octanoyltransferase (2.3.1.204)
C12Y203/01207	2	Beta-ketodecanoyl-[acyl-carrier-protein] synthase (2.3.1.207)
C12Y203/02005	2	Glutaminyl-peptide cyclotransferase (2.3.2.5)
C12Y203/02013	2	Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
C12Y203/02019	2	Ribostamycin:4-(gamma-L-glutamylamino)-(S)-2-hydroxybutanoyl-[BtrI acyl-carrier protein] 4-(gamma-L-glutamylamino)-(S)-2-hydroxybutanoate transferase (2.3.2.19)
C12Y204/01041	2	Polypeptide N-acetylgalactosaminyltransferase (2.4.1.41)
C12Y204/01094	2	Protein N-acetylglucosaminyltransferase (2.4.1.94)
C12Y204/01109	2	Dolichyl-phosphate-mannose-protein mannosyltransferase (2.4.1.109)
C12Y204/01113	2	Alpha-1,4-glucan-protein synthase (ADP-forming) (2.4.1.113)
C12Y204/01221	2	Peptide-O-fucosyltransferase (2.4.1.221)
C12Y204/01229	2	[Skp1-protein]-hydroxyproline N-acetylglucosaminyltransferase (2.4.1.229)
C12Y204/01255	2	Protein O-GlcNAc transferase (2.4.1.255)
C12Y204/02026	2	Protein xylosyltransferase (2.4.2.26)
C12Y204/02031	2	NAD+-protein-arginine ADP-ribosyltransferase (2.4.2.31)
C12Y204/02033	2	Dolichyl-xylosyl-phosphate--protein xylosyltransferase (2.4.2.33)
C12Y204/99018	2	Dolichyl-diphosphooligosaccharideprotein glycotransferase (2.4.99.18)
C12Y204/99019	2	Undecaprenyl-diphosphooligosaccharideprotein glycotransferase (2.4.99.19)
C12Y205/01058	2	Protein farnesyltransferase (2.5.1.58)
C12Y205/01059	2	Protein geranylgeranyltransferase type I (2.5.1.59)
C12Y205/0106	2	Protein geranylgeranyltransferase type II (2.5.1.60)
C12Y207/01037	2	Protein kinase (2.7.1.37) (C12Y207/11001, C12Y207/11008 - C12Y207/11013, C12Y207/11021, C12Y207/11022, C12Y207/11024, C12Y207/11025, C12Y207/1103, C12Y207/12001 take precedence)
C12Y207/01069	2	Protein-Npi-phosphohistidine-sugar phosphotransferase (2.7.1.69), i.e. sucrose phosphotransferase system II
C12Y207/01112	2	Protein-tyrosine kinase (2.7.1.112) (C12Y207/10001, C12Y207/10002 take precedence)
C12Y207/01171	2	Protein-fructosamine 3-kinase (2.7.1.171)
C12Y207/01172	2	Protein-ribulosamine 3-kinase (2.7.1.172)
C12Y207/03009	2	Phosphoenolpyruvate-protein phosphotransferase (2.7.3.9)
C12Y207/07059	2	[Protein-PII] uridylyltransferase (2.7.7.59)
C12Y207/07061	2	Citrate lyase holo-[acyl-carrier-protein] synthase (2.7.7.61)
C12Y207/07063	2	Lipoate--protein ligase (2.7.7.63)
C12Y207/07066	2	Malonate decarboxylase holo-[acyl-carrier-protein] synthase (2.7.7.66)
C12Y207/07073	2	Sulfur carrier protein ThiS adenylyltransferase (2.7.7.73)
C12Y207/08007	2	Holo-[acyl-carrier-protein] synthase (2.7.8.7)
C12Y207/10	1	Protein-tyrosine kinases (2.7.10)
C12Y207/10001	2	Receptor protein-tyrosine kinase (2.7.10.1)
C12Y207/10002	2	Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
C12Y207/11	1	Protein-serine/threonine kinases (2.7.11)
C12Y207/11001	2	Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
C12Y207/11009	2	Goodpasture-antigen-binding protein kinase (2.7.11.9)
C12Y207/11011	2	cAMP-dependent protein kinase (2.7.11.11)
C12Y207/11012	2	cGMP-dependent protein kinase (2.7.11.12)
C12Y207/11013	2	Protein kinase C (2.7.11.13)
C12Y207/11016	2	G-Protein-coupled receptor kinase (2.7.11.16)
C12Y207/11017	2	Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
C12Y207/11024	2	Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
C12Y207/11025	2	Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
C12Y207/11026	2	Tau-protein kinase (2.7.11.26)
C12Y207/1103	2	Receptor protein serine/threonine kinase (2.7.11.30)
C12Y207/12002	2	Mitogen-activated protein kinase kinase (2.7.12.2), i.e. MAPKK or MEK1 or MEK2
C12Y207/13	1	Protein-histidine kinases (2.7.13)
C12Y207/13001	2	Protein-histidine pros-kinase (2.7.13.1)
C12Y207/13002	2	Protein-histidine tele-kinase (2.7.13.2)
C12Y207/99	1	Other protein kinases (2.7.99)
C12Y207/99001	2	Triphosphate--protein phosphotransferase (2.7.99.1)
C12Y208/0202	2	Protein-tyrosine sulfotransferase (2.8.2.20)
C12Y301/01061	2	Protein-glutamate methylesterase (3.1.1.61)
C12Y301/01085	2	Pimelyl-[acyl-carrier protein] methyl ester esterase (3.1.1.85)
C12Y301/01089	2	Protein phosphatase methylesterase-1 (3.1.1.89)
C12Y301/02014	2	Oleoyl-[acyl-carrier-protein] hydrolase (3.1.2.14), i.e. ACP-thioesterase
C12Y301/02021	2	Dodecanoyl-[acyl-carrier-protein] hydrolase (3.1.2.21)
C12Y301/02022	2	Palmitoyl-protein hydrolase (3.1.2.22)
C12Y301/03048	2	Protein-tyrosine-phosphatase (3.1.3.48)
C12Y301/04014	2	[Acyl-carrier-protein] phosphodiesterase (3.1.4.14)
C12Y302/01107	2	Protein-glucosylgalactosylhydroxylysine glucosidase (3.2.1.107)
C12Y302/01169	2	Protein O-GlcNAcase (3.2.1.169)
C12Y302/02019	2	Protein ADP-ribosylarginine hydrolase (3.2.2.19)
C12Y304/00	0	Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
C12Y304/21069	2	Protein C activated (3.4.21.69)
C12Y304/21113	2	Pestivirus NS3 polyprotein peptidase (3.4.21.113)
C12Y305/00	0	Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
C12Y305/01044	2	Protein-glutamine glutaminase (3.5.1.44)
C12Y305/01052	2	Peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase (3.5.1.52), i.e. glycopeptidase
C12Y305/01088	2	Peptide deformylase (3.5.1.88)
C12Y305/03015	2	Protein-arginine deiminase (3.5.3.15)
C12Y306/03043	2	Peptide-transporting ATPase (3.6.3.43)
C12Y306/0305	2	Protein-secreting ATPase (3.6.3.50)
C12Y306/03051	2	Mitochondrial protein-transporting ATPase (3.6.3.51)
C12Y306/03052	2	Chloroplast protein-transporting ATPase (3.6.3.52)
C12Y306/05001	2	Heterotrimeric G-protein GTPase (3.6.5.1)
C12Y306/05003	2	Protein-synthesizing GTPase (3.6.5.3)
C12Y401/01095	2	L-Glutamyl-[BtrI acyl-carrier protein] decarboxylase (4.1.1.95)
C12Y402/01059	2	3-Hydroxyacyl-[acyl-carrier-protein] dehydratase (4.2.1.59)
C12Y402/01134	2	Very-long-chain (3R)-3-hydroxyacyl-[acyl-carrier protein] dehydratase (4.2.1.134)
C12Y501/01	1	acting on amino acids and derivatives (5.1.1)
C12Y501/01016	2	Protein-serine epimerase (5.1.1.16)
C12Y503/03014	2	Trans-2-decenoyl-[acyl-carrier-protein] isomerase (5.3.3.14)
C12Y503/04001	2	Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
C12Y602/0102	2	Long-chain-fatty-acid--[acyl-carrier-protein] ligase (6.2.1.20)
C12Y602/01039	2	[Butirosin acyl-carrier protein]L-glutamate ligase (6.2.1.39)
C12Y603/02	1	Acidamino-acid ligases (peptide synthases)(6.3.2)
C12Y603/02019	2	Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
C22B3/1625	5	{with amines (amino acids C22B3/165)}
C25B7/00	0	Electrophoretic production of compounds or non-metals (separation or purification of peptides, e.g. of proteins, by electrophoresis C07K1/26)
C40B		COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
C40B10/00	0	Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
C40B40/08	3	Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
C40B40/10	2	Libraries containing peptides or polypeptides, or derivatives thereof
D01F4/00	0	Monocomponent artificial filaments or the like of proteins; Manufacture thereof
D01F4/06	1	from globulins, e.g. groundnut protein
D01F6/60	2	from polyamides (from polyamino acids or polypeptides D01F6/68)
D01F6/68	2	from polyaminoacids or polypeptides
D01F8/02	1	from cellulose, cellulose derivatives, or proteins
D01F9/18	4	from proteins, e.g. from wool
D01F9/326	5	{for manufacturing filaments from proteins}
D01F11/02	1	of cellulose, cellulose derivatives, or proteins
D01F13/02	1	of cellulose, cellulose derivatives or proteins {(recovery of sodium sulfate from coagulation baths C01D5/006)}
D03D15/233	2	protein-based, e.g. wool or silk
D06M15/15	2	Proteins or derivatives thereof
D06N3/12	1	with macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {, e.g. gelatine proteins}
D06N3/126	3	{Poly-amino acids, e.g. polyglutamates}
D10B2211/00	0	Protein-based fibres, e.g. animal fibres
D10B2211/20	1	Protein-derived artificial fibres
D10B2211/26	2	Globulin, e.g. groundnut protein
D10B2331/08	1	polyamino acids or polypeptides
D21H5/1209	2	{of protein fibres}
D21H13/34	3	Protein fibres
D21H17/02	1	Material of vegetable origin (proteins D21H17/22; lignins D21H17/23; polysaccharides D21H17/24; rosin D21H17/62)
D21H17/22	3	Proteins
D21H19/50	3	Proteins
G01N24/087	2	{Structure determination of a chemical compound, e.g. of a biomolecule such as a protein}
G01N2030/8818	5	{involving amino acids}
G01N2030/8831	5	{involving peptides or proteins}
G01N33/566	4	using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
G01N33/57476	5	{involving oncofetal proteins}
G01N33/5748	5	{involving oncogenic proteins}
G01N33/57484	5	{involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites}
G01N33/68	3	involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
G01N33/6803	4	{General methods of protein analysis not limited to specific proteins or families of proteins}
G01N33/6806	5	{Determination of free amino acids}
G01N33/6809	6	{involving fluorescent derivatizing reagents reacting non-specifically with all amino acids}
G01N33/6812	6	{Assays for specific amino acids}
G01N33/6818	5	{Sequencing of polypeptides}
G01N33/6827	5	{Total protein determination, e.g. albumin in urine}
G01N33/6842	5	{Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
G01N33/6845	5	{Methods of identifying protein-protein interactions in protein mixtures}
G01N33/6848	5	{Methods of protein analysis involving mass spectrometry}
G01N33/6851	6	{Methods of protein analysis involving laser desorption ionisation mass spectrometry}
G01N33/6863	4	{Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
G01N33/6872	4	{Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
G01N33/74	3	involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
G01N2333/003	2	of Peptide-nucleic acids (PNAs)
G01N2333/163	6	Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
G01N2333/325	3	Bacillus thuringiensis crystal protein (delta-endotoxin)
G01N2333/47	3	Assays involving proteins of known structure or function as defined in the subgroups
G01N2333/4707	7	Guanosine triphosphatase activating protein, GAP
G01N2333/4709	5	Amyloid plaque core protein
G01N2333/471	5	Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
G01N2333/4712	5	Muscle proteins, e.g. myosin, actin, protein
G01N2333/4715	5	Cytokine-induced proteins
G01N2333/4716	5	Complement proteins, e.g. anaphylatoxin, C3a, C5a
G01N2333/4719	5	G-proteins
G01N2333/4721	5	Cationic antimicrobial peptides, e.g. defensins
G01N2333/4727	5	Calcium binding proteins, e.g. calmodulin
G01N2333/4733	5	Acute pancreatitis-associated protein
G01N2333/4736	5	Retinoblastoma protein
G01N2333/4737	5	C-reactive protein
G01N2333/474	5	Pancreatic thread protein; Reg protein
G01N2333/4743	5	Bactericidal/Permeability-increasing protein BPI
G01N2333/4745	5	Insulin-like growth factor binding protein
G01N2333/5753	3	Calcitonin gene related peptide
G01N2333/5757	3	Vasoactive intestinal peptide [VIP] or related peptides
G01N2333/5758	3	Gastrin releasing peptide
G01N2333/5759	3	Thymosin or related peptides
G01N2333/58	3	Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
G01N2333/635	3	Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
G01N2333/665	2	Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
G01N2333/726	4	G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
G01N2333/7458	3	Protein S
G01N2333/78	2	Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
G01N2333/785	2	Alveolar surfactant peptides; Pulmonary surfactant peptides
G01N2333/795	1	Porphyrin- or corrin-ring-containing peptides
G01N2333/90209	3	acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
G01N2333/90258	4	with a reduced iron-sulfur protein as one donor (1.14.15) in general
G01N2333/90264	6	Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
G01N2333/90644	7	D-Amino acid oxidase (1.4.3.3)
G01N2333/948	3	acting on peptide bonds (3.4)
G01N2333/96461	11	Protein C (3.4.21.69)
G01N2333/978	3	acting on carbon to nitrogen bonds other than peptide bonds (3.5)
G01N2410/00	0	Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
G01N2410/02	1	Angiotensins; Related peptides
G01N2410/04	1	Oxytocins; Vasopressins; Related peptides
G01N2410/06	1	Kallidins; Bradykinins; Related peptides
G01N2410/08	1	Cyclosporins and related peptides
G01N2430/60	1	Synthetic polymers other than synthetic polypeptides as analytes
G01N2440/34	1	addition of amino acid(s), e.g. arginylation, (poly-)glutamylation, (poly-)glycylation
G01N2440/36	1	addition of addition of other proteins or peptides, e.g. SUMOylation, ubiquitination
G01N2496/45	1	containing protease inhibitors, e.g. sulfonylfluorides, chloromethylketones, organophosphates (peptide-based protease inhibitors G01N2333/81)
G01N2550/00	0	Electrophoretic profiling, e.g. for proteome analysis
G01N2650/00	0	Assays involving polymers whose constituent monomers bore biological functional groups before polymerization, i.e. vinyl, acryl derivatives of amino acids, sugars
G01N2800/60	1	Complex ways of combining multiple protein biomarkers for diagnosis
G01N2800/7076	4	Amino acid metabolism
G03C1/047	3	Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
G03F7/0215	5	{Natural gums; Proteins, e.g. gelatins; Macromolecular carbohydrates, e.g. cellulose; Polyvinyl alcohol and derivatives thereof, e.g. polyvinylacetals}
G03G7/0033	4	{Natural products or derivatives thereof, e.g. cellulose, proteins}
G06N3/002	1	{Biomolecular computers, i.e. using biomolecules, proteins, cells (using DNA G06N3/123; using neurons G06N3/061)}
G16B		BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
G16B5/00	0	ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B15/20	1	Protein or domain folding
G16B25/00	0	ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
G16B25/10	1	Gene or protein expression profiling; Expression-ratio estimation or normalisation
G16B30/00	0	ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B35/00	0	ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
Y10S210/905	3	Protein
Y10S424/80	1	Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
Y10S424/832	1	involving bacterial toxin that has modified amino acid sequence
Y10S435/804	1	Single cell protein
Y10S436/802	1	Protein-bacteriophage conjugates
Y10S436/828	1	Protein A
Y10S502/507	2	Synthetic resin, natural resin, polysaccaride, or polypeptide
Y10S516/04	3	Protein or carboxylic compound containing
Y10S516/06	2	Protein or carboxylic compound containing
Y10S528/932	2	Protein removal or conversion
Y10S530/00	0	Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Y10S530/80	1	Antihypertensive peptides
Y10S530/801	1	Peptide sweetners
Y10S530/802	1	Chromogenic or luminescent peptides
Y10S530/806	1	Antigenic peptides or proteins
Y10S530/807	1	Hapten conjugated with peptide or protein
Y10S530/81	1	Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
Y10S530/811	2	Peptides or proteins is immobilized on, or in, an inorganic carrier
Y10S530/812	2	Peptides or proteins is immobilized on, or in, an organic carrier
Y10S530/82	1	Proteins from microorganisms
Y10S530/827	1	Proteins from mammals or birds
Y10S530/855	1	Proteins from animals other than mammals or birds
Y10S930/00	0	Peptide or protein sequence
Y10S930/01	1	Peptide or protein sequence
Y10S930/02	2	Containing modified or unusual amino acid
Y10S930/021	3	Containing D-amino acid
Y10S930/03	2	Linear peptide or protein containing a nonpeptide or abnormal peptide link
Y10S930/04	2	Angiotensin; related peptides
Y10S930/05	2	Atrial or brain natriuretic peptide; related peptides
Y10S930/06	2	Calcitonin; related peptides
Y10S930/07	2	Corticotropin; related peptides
Y10S930/08	2	Endorphin or enkephalin; related peptides
Y10S930/09	2	Erythropoietin; related peptides
Y10S930/10	2	Factor VIII, AHF; related peptides
Y10S930/11	2	Gonadotropin; related peptides
Y10S930/12	2	Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Y10S930/13	2	Luteinizing hormone-releasing hormone; related peptides
Y10S930/14	2	Lymphokine; related peptides
Y10S930/15	2	Oxytocin or vasopressin; related peptides
Y10S930/16	2	Somatostatin; related peptides
Y10S930/17	2	Vasoactive intestinal peptides; related peptides
Y10S930/18	2	Thymus derived hormone or factor; related peptides
Y10S930/20	2	Bacterial peptide or bacterial protein
Y10S930/21	2	Parasitic peptide or parasitic protein
Y10S930/22	2	Viral peptide or viral protein
Y10S930/23	2	Multicellular plant peptide or multicellular plant protein
Y10S930/27	2	Cyclic peptide or cyclic protein
Y10S930/29	2	Polyamino acid or polypeptide with an uninterrupted series of peptide repeating units
Y10S977/705	4	Protein or peptide
Y10S977/714	4	Containing protein
Y10S977/729	4	From protein or unit thereof, e.g. enzyme or carboxyl group
Y10S977/757	4	Layer containing protein
Y10S977/793	6	Protein array
Y10S977/886	4	Via protein recognition
Y10S977/914	3	Protein engineering
Y10S977/942	4	including protein logic element
Y10S977/945	5	Protein memory
Y10T428/2865	3	including monomer or polymer of carbohydrate [e.g., starch, dextrin, etc.] Or protein [e.g., casein, animal protein, etc.] Or derivative thereof
Y10T436/105831	2	Protein or peptide standard or control [e.g., hemoglobin, etc.]
A23L27/39	2	{Addition of sweetness inhibitors}
A23L27/86	1	{Addition of bitterness inhibitors}
A23V2200/332	2	Promoters of weight control and weight loss
A61F2002/0091	3	{Having cellular growth inhibitors}
A61F2007/0293	3	{Triggers, activators or catalysts therefor}
A61K38/005	1	{Enzyme inhibitors (protease inhibitors A61K38/55)}
A61K38/04	1	Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005}; gastrins {A61K38/2207} somatostatins A61K38/31, melanotropins A61K38/34; {protease inhibitors A61K38/55})
A61K38/16	1	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
A61K38/17	2	from animals; from humans {(enzyme inhibitors A61K38/005)}
A61K38/1761	5	{Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2}
A61K38/177	3	{Receptors; Cell surface antigens; Cell surface determinants}
A61K38/1774	4	{Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
A61K38/1783	4	{Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
A61K38/1787	4	{for neuromediators, e.g. serotonin receptor, dopamine receptor}
A61K38/49	5	Urokinase; Tissue plasminogen activator
A61K38/55	2	Protease inhibitors
A61K38/553	3	{Renin inhibitors}
A61K38/556	3	{Angiotensin converting enzyme inhibitors}
A61K39/001102	3	{Receptors, cell surface antigens or cell surface determinants}
A61K39/001103	4	{Receptors for growth factors}
A61K39/001104	5	{Epidermal growth factor receptors [EGFR]}
A61K39/001107	5	{Fibroblast growth factor receptors [FGFR]}
A61K39/001108	5	{Platelet-derived growth factor receptors [PDGFR]}
A61K39/001109	5	{[Vascular endothelial growth factor receptors [VEGFR]}
A61K39/00111	5	{Hepatocyte growth factor receptor [HGFR or c-met]}
A61K39/001116	4	{Receptors for cytokines}
A61K39/001117	5	{Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
A61K39/001118	5	{Receptors for colony stimulating factors [CSF]}
A61K39/001119	5	{Receptors for interleukins [IL]}
A61K39/00112	5	{Receptors for interferons [IFN]}
A61K39/001121	5	{Receptors for chemokines }
A61K39/001122	4	{Ephrin Receptors [Eph]}
A61K39/001152	3	{Transcription factors, e.g. SOX, c-MYC}
A61K47/6425	5	{the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
A61K47/6849	5	{the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
A61K48/0058	2	{Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
A61K51/083	4	{the peptide being octreotide or a somatostatin-receptor-binding peptide}
A61K51/1027	5	{against receptors, cell-surface antigens or cell-surface determinants}
A61K51/103	6	{against receptors for growth factors or receptors for growth regulators}
A61K51/1033	6	{against receptors for cytokines, lymphokines or interferons}
A61K51/1036	6	{against hormone receptors}
A61K51/1039	6	{against T-cell receptors}
A61K51/1042	7	{against T-cell receptor (TcR)-CD3 complex}
A61K2800/526	3	Corrosion inhibitors
A61K2800/782	3	Enzyme inhibitors; Enzyme antagonists
A61L33/0011	2	{Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate}
A61L2300/432	2	Inhibitors, antagonists (A61L2300/402-A61L2300/43 take precedence)
A61L2300/436	3	of receptors
A61P1/04	1	for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P7/02	1	Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P15/08	1	for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A62D2101/02	1	Chemical warfare substances, e.g. cholinesterase inhibitors
B01D21/265	2	{by using a vortex inducer or vortex guide, e.g. coil (B01D21/0054 takes precedence)}
B01D2247/108	2	using vortex inducers
B01D2252/602	2	Activators, promoting agents, catalytic agents or enzymes
B01D2323/32	1	Use of chain transfer agents or inhibitors
B01J2219/00272	3	Addition of reaction inhibitor
B01J2531/007	3	Promoter-type Additives
B22F2003/1032	2	{comprising a grain growth inhibitor}
B29C64/165	2	using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
B29C64/291	3	for operating globally, e.g. together with selectively applied activators or inhibitors
B29D11/00817	3	{Producing electro-active lenses or lenses with energy receptors, e.g. batteries or antennas}
B29D11/00826	4	{with energy receptors for wireless energy transmission}
B32B2307/752	2	Corrosion inhibitor
B41M5/20	1	using electric current (B41M5/24 takes precedence {; processes in which the current is transformed into a heat pattern for obtaining transfer to a receptor sheet B41M5/382; electro-coagulable or electro-adhesive printing or recording B41C1/105})
B41M5/38257	3	{characterised by the use of an intermediate receptor}
B41M2205/08	1	Ablative thermal transfer, i.e. the exposed transfer medium is propelled from the donor to a receptor by generation of a gas
B63B2021/504	3	{comprising suppressors for vortex induced vibrations}
B64D2033/045	2	{comprising infrared suppressors}
B65B55/19	3	by adding materials intended to remove free oxygen or to develop inhibitor gases, e.g. vapour phase inhibitors
B65D77/2064	6	{the seal being locally weakened, e.g. by using a sealing inhibitor}
B65D81/26	2	with provision for draining away, or absorbing, {or removing by ventilation,} fluids, e.g. exuded by contents {(B65D33/01 takes precedence)}; Applications of corrosion inhibitors or desiccators
B65H2553/412	3	in barrier arrangements, i.e. emitter facing a receptor element
B65H2553/414	3	involving receptor receiving light reflected by a reflecting surface and emitted by a separate emitter
C01B2203/1094	3	Promotors or activators
C04B7/153	3	Mixtures thereof with other inorganic cementitious materials or other activators
C04B7/1535	4	{with alkali metal containing activators, e.g. sodium hydroxide or waterglass}
C04B7/17	4	with calcium oxide containing activators {(C04B7/1535 takes precedence)}
C04B7/21	4	with calcium sulfate containing activators {(C04B7/1535 takes precedence)}
C04B7/243	2	{Mixtures thereof with activators or composition-correcting additives, e.g. mixtures of fly ash and alkali activators}
C04B40/0633	2	{Chemical separation of ingredients, e.g. slowly soluble activator}
C04B2103/10	1	Accelerators; Activators
C04B2103/61	2	Corrosion inhibitors
C07K5/0227	2	{containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06-C07K5/10}
C07K14/4703	6	{Inhibitors; Suppressors}
C07K14/705	2	Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
C07K14/7051	4	{T-cell receptor (TcR)-CD3 complex}
C07K14/70535	4	{Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
C07K14/70567	3	{Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
C07K14/70571	3	{for neuromediators, e.g. serotonin receptor, dopamine receptor}
C07K14/70578	3	{NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
C07K14/721	4	{Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
C07K14/723	4	{G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor}
C07K14/81	1	Protease inhibitors
C07K14/8103	2	{Exopeptidase (E.C. 3.4.11-19) inhibitors}
C07K14/8107	2	{Endopeptidase (E.C. 3.4.21-99) inhibitors}
C07K14/811	3	{Serine protease (E.C. 3.4.21) inhibitors}
C07K14/8114	4	{Kunitz type inhibitors}
C07K14/8117	5	{Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)}
C07K14/8132	5	{Plasminogen activator inhibitors}
C07K14/8135	4	{Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid}
C07K14/8139	3	{Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin}
C07K14/8142	3	{Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors}
C07K14/8146	3	{Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP}
C07K16/28	2	against receptors, cell surface antigens or cell surface determinants
C07K16/2809	4	{against the T-cell receptor (TcR)-CD3 complex}
C07K16/283	4	{against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
C07K16/2857	3	{against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor}
C07K16/286	3	{against neuromediator receptors, e.g. serotonin receptor, dopamine receptor}
C07K16/2863	3	{against receptors for growth factors, growth regulators}
C07K16/2866	3	{against receptors for cytokines, lymphokines, interferons}
C07K16/2869	3	{against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
C07K16/2878	3	{against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
C07K16/38	1	against protease inhibitors of peptide structure
C07K16/4258	4	{against anti-receptor Ig}
C07K16/4266	5	{against anti-tumor receptor Ig}
C07K2317/32	2	specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
C07K2319/32	1	fusions with soluble part of a cell surface receptor, "decoy receptors"
C07K2319/715	3	containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
C07K2319/74	2	containing a fusion for binding to a cell surface receptor
C07K2319/75	3	containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
C07K2319/80	1	containing a DNA binding domain, e.g. Lacl or Tet-repressor
C08F2/005	2	{by addition of a scale inhibitor to the polymerisation medium}
C09K2208/22	1	Hydrates inhibition by using well treatment fluids containing inhibitors of hydrate formers
C10G75/02	1	by addition of corrosion inhibitors
C10L2230/08	1	Inhibitors
C11D3/3905	3	{Bleach activators; Bleach catalysts}
C12M1/21	1	Froth suppressors
C12N9/6456	7	{Plasminogen activators}
C12N9/6459	8	{t-plasminogen activator (3.4.21.68), i.e. tPA}
C12N9/6462	8	{u-Plasminogen activator (3.4.21.73), i.e. urokinase}
C12N15/1135	4	{against oncogenes or tumor suppressor genes}
C12N15/1137	4	{against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
C12N15/1138	4	{against receptors or cell surface proteins}
C12N15/635	3	{Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
C12N15/8223	7	{Vegetative tissue-specific promoters}
C12N15/823	7	{Reproductive tissue-specific promoters}
C12N2501/01	1	Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
C12N2501/38	2	with nuclear receptors
C12N2501/385	3	of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
C12N2501/41	2	Hedgehog proteins; Cyclopamine (inhibitor)
C12N2501/515	2	CD3, T-cell receptor complex
C12N2501/60	1	Transcription factors
C12N2800/60	1	Vectors containing traps for, e.g. exons, promoters
C12N2810/855	4	from receptors; from cell surface antigens; from cell surface determinants
C12N2830/001	1	controllable enhancer/promoter combination
C12N2830/002	2	inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
C12N2830/005	2	repressible enhancer/promoter combination, e.g. KRAB
C12N2830/007	1	cell cycle specific enhancer/promoter combination
C12N2830/008	1	cell type or tissue specific enhancer/promoter combination
C12N2830/15	1	chimeric enhancer/promoter combination
C12N2830/30	1	being an enhancer not forming part of the promoter region
C12N2830/32	1	being an silencer not forming part of the promoter region
C12Q1/6865	3	Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
C12Q1/6897	2	involving reporter genes operably linked to promoters
C12Q2525/143	2	incorporating a promoter sequence
C12Q2527/127	1	the enzyme inhibitor or activator used
C12Q2531/143	2	Promoter based amplification, e.g. NASBA, 3SR, TAS
C12Y207/10001	2	Receptor protein-tyrosine kinase (2.7.10.1)
C12Y207/11015	2	[Beta-adrenergic-receptor] kinase (2.7.11.15)
C12Y207/11016	2	G-Protein-coupled receptor kinase (2.7.11.16)
C12Y207/11029	2	[Low-density-lipoprotein receptor] kinase (2.7.11.29)
C12Y207/1103	2	Receptor protein serine/threonine kinase (2.7.11.30)
C12Y304/21068	2	Tissue plasminogen activator (3.4.21.68), i.e. tPA
C12Y304/21073	2	u-Plasminogen activator (3.4.21.73), i.e. urokinase
C12Y304/21088	2	Repressor LexA (3.4.21.88)
C12Y304/21095	2	Snake venom factor V activator (3.4.21.95)
C12Y304/23048	2	Plasminogen activator Pla (3.4.23.48)
C23C16/45534	6	{Use of auxiliary reactants other than used for contributing to the composition of the main film, e.g. catalysts, activators or scavengers}
C23F11/00	0	Inhibiting corrosion of metallic material by applying inhibitors to the surface in danger of corrosion or adding them to the corrosive agent (adding inhibitors to mineral oil, fuels, or lubricants C10; adding inhibitors to pickling solutions C23G)
C23F11/02	1	in air or gases by adding vapour phase inhibitors
C23F11/10	2	using organic inhibitors
C23F11/18	2	using inorganic inhibitors
C23F11/187	3	{Mixtures of inorganic inhibitors}
C23G1/04	2	using inhibitors
C23G1/06	3	organic inhibitors
C23G1/16	2	using inhibitors
C23G1/18	3	Organic inhibitors
C23G1/26	2	using inhibitors
C23G1/30	2	using inhibitors
C40B30/04	1	by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
D06N7/0015	4	{use of inhibitor for the blowing agent or inhibitor for the kicker, e.g. trimellitic anhydride, triazole}
E04H4/143	2	{Swimming lane markers with or without wave suppressors}
F02K1/822	3	{Heat insulating structures or liners, cooling arrangements, e.g. post combustion liners; Infra-red radiation suppressors}
F02K1/825	4	{Infra-red radiation suppressors}
F02K9/346	4	{Liners, e.g. inhibitors}
G01N24/088	2	{Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics}
G01N27/3276	6	{being a hybridisation with immobilised receptors (using a FET type sensor G01N27/4145; concerning the hybridisation C12Q1/68)}
G01N27/4145	4	{specially adapted for biomolecules, e.g. gate electrode with immobilised receptors}
G01N2030/965	2	{suppressor columns}
G01N33/535	6	with enzyme label {or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates}
G01N33/566	4	using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
G01N33/57484	5	{involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites}
G01N33/581	4	{with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)}
G01N33/6863	4	{Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
G01N33/6872	4	{Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
G01N33/74	3	involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
G01N33/76	4	Human chorionic gonadotropin {including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors}
G01N33/78	4	Thyroid gland hormones {, e.g. T3, T4, TBH, TBG or their receptors}
G01N33/82	3	involving vitamins {or their receptors}
G01N33/86	3	involving blood coagulating time {or factors, or their receptors}
G01N33/88	3	involving prostaglandins {or their receptors}
G01N33/92	3	involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
G01N33/94	3	involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
G01N2333/4704	6	Inhibitors; Supressors
G01N2333/705	2	Assays involving receptors, cell surface antigens or cell surface determinants
G01N2333/7051	4	T-cell receptor (TcR)-CD3 complex
G01N2333/70535	4	Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
G01N2333/70567	3	Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
G01N2333/70571	3	for neuromediators, e.g. serotonin receptor, dopamine receptor
G01N2333/70578	3	NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95 (NGF-receptor G01N2333/71, TNF-receptor G01N2333/7151)
G01N2333/723	4	Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
G01N2333/726	4	G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
G01N2333/81	1	Protease inhibitors
G01N2333/8103	2	Exopeptidase (E.C. 3.4.11-19) inhibitors
G01N2333/8107	2	Endopeptidase (E.C. 3.4.21-99) inhibitors
G01N2333/811	3	Serine protease (E.C. 3.4.21) inhibitors
G01N2333/8114	4	Kunitz type inhibitors
G01N2333/8117	5	Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
G01N2333/8132	5	Plasminogen activator inhibitors
G01N2333/8135	4	Kazal type inhibitors, e.g. pancreatic secretory inhibitor or ovomucoid
G01N2333/8139	3	Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
G01N2333/8142	3	Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
G01N2333/8146	3	Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
G01N2333/972	4	Plasminogen activators
G01N2333/9726	5	Tissue plasminogen activator
G01N2496/45	1	containing protease inhibitors, e.g. sulfonylfluorides, chloromethylketones, organophosphates (peptide-based protease inhibitors G01N2333/81)
G01N2500/02	1	Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
G01N2500/04	1	Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
G03C1/34	3	Fog-inhibitors; Stabilisers; Agents inhibiting latent image regression
G03C2007/30564	4	{Development inhibitor releasing}
G03F7/0045	2	{with organic non-macromolecular light-sensitive compounds not otherwise provided for, e.g. dissolution inhibitors}
G03G5/09	3	Sensitisors or activators, e.g. dyestuffs (G03G5/12 takes precedence)
G05B2219/32372	3	Petrinet, coloured, inhibitor arc, timed, object token Petrinet
G08B13/2474	6	{Antenna or antenna activator geometry, arrangement or layout (loop antennae H01Q1/22)}
G08B13/2477	6	{Antenna or antenna activator circuit}
G08B25/016	2	{Personal emergency signalling and security systems (emergency non-personal manually actuated alarm activators G08B25/12)}
G08B25/12	1	Manually actuated calamity alarm transmitting arrangements {emergency non-personal manually actuated alarm, activators, e.g. details of alarm push buttons mounted on an infrastructure}
G21C17/0225	3	{Chemical surface treatment, e.g. corrosion (corrosion prevention in presence of water from scale removal or by modification of the properties of the liquid C02F5/00; inhibiting corrosion by adding corrosion inhibitors C23F11/00)}
H01M4/628	3	{Inhibitors, e.g. gassing inhibitors, corrosion inhibitors}
H01S3/1691	3	{characterised by additives / sensitisers / promoters as further dopants}
H02K11/026	2	Suppressors associated with brushes, brush holders or their supports
H02K11/028	2	Suppressors associated with the rotor
H02K13/105	2	{Spark suppressors associated with the commutator}
H04J3/175	2	{Speech activity or inactivity detectors (echo suppressors H04B3/20)}
H04M3/002	1	{Applications of echo suppressors or cancellers in telephonic connections (in two-way loud-speaking telephone systems H04M9/08, echo suppressors or cancellers per se H04B3/20)}
H04Q2213/1319	1	Amplifier, attenuation circuit, echo suppressor
H05B33/18	2	characterised by the nature or concentration of the activator
H05K9/0066	1	{Constructional details of transient suppressor}
Y10S430/118	4	with inhibitor or stabilizer
Y10S430/158	2	Development inhibitor releaser, DIR
Y10S507/934	2	with inhibitor
Y10S507/939	1	Corrosion inhibitor
Y10S514/889	1	Interferon inducer
Y10S530/86	1	Renin inhibitors
Y10S930/25	2	Enzyme inhibitor
Y10T29/53039	2	with control means energized in response to activator stimulated by condition sensor
Y10T156/1722	4	Means applying fluent adhesive or adhesive activator material between layers
Y10T156/1798	2	with liquid adhesive or adhesive activator applying means
Y10T408/16	1	with control means energized in response to activator stimulated by condition sensor
Y10T409/102226	4	with control means energized in response to activator stimulated by condition sensor
Y10T409/304648	3	with control means energized in response to activator stimulated by condition sensor
Y10T409/306832	4	with infeed control means energized in response to activator stimulated by condition sensor
Y10T409/307224	3	with infeed control means energized in response to activator stimulated by condition sensor
Y10T409/308008	4	with control for adjustment means responsive to activator stimulated by condition sensor
Y10T409/40035	2	with control means energized in response to activator stimulated by condition sensor
Y10T483/13	1	with control means energized in response to activator stimulated by condition sensor
A01K2207/05	1	Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
A01K2207/20	1	Animals treated with compounds which are neither proteins nor nucleic acids
A01K2217/05	1	Animals comprising random inserted nucleic acids (transgenic)
A01K2217/058	3	due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
A01N63/60	1	Isolated nucleic acids
A21D2/245	3	{Amino acids, nucleic acids}
A23C9/1322	3	{Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins}
A23C9/1526	2	{Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof}
A23C19/0921	3	{Addition, to cheese or curd, of minerals, including organic salts thereof, trace elements, amino acids, peptides, protein hydrolysates, nucleic acids, yeast extracts or autolysate, vitamins or derivatives of these compounds}
A23K20/153	2	Nucleic acids; Hydrolysis products or derivatives thereof
A23L13/428	3	{Addition of flavours, spices, colours, amino acids or their salts, peptides, vitamins, yeast extract or autolysate, nucleic acid or derivatives, organic acidifying agents or their salts or acidogens, sweeteners, e.g. sugars or sugar alcohols; Addition of alcohol-containing products}
A23L27/23	2	containing nucleotides
A23L27/31	2	{containing amino acids, nucleotides, peptides or derivatives}
A23L33/13	2	Nucleic acids or derivatives thereof (A23L33/145 takes precedence)
A61K8/606	4	{Nucleosides; Nucleotides; Nucleic acids}
A61K31/7052	3	having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K31/7084	2	Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
A61K31/7088	2	Compounds having three or more nucleosides or nucleotides
A61K31/7105	3	Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K31/7115	3	Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K31/712	3	Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K31/7125	3	Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K31/713	3	Double-stranded nucleic acids or oligonucleotides
A61K2039/6025	2	{Nucleotides}
A61K41/0057	1	{Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
A61K47/26	2	Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K47/549	4	{Sugars, nucleosides, nucleotides or nucleic acids}
A61K47/6455	6	{Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
A61K47/6807	6	{the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
A61K48/0016	2	{wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid}
A61K48/0025	2	{wherein the non-active part clearly interacts with the delivered nucleic acid}
A61K48/005	1	{characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
A61K48/0058	2	{Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
A61K48/0066	2	{Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
A61K51/0489	3	{Phosphates or phosphonates, e.g. bone-seeking phosphonates; (phospholipids: A61K51/0408; nucleotides or nucleic acids: A61K51/0491)}
A61K51/0491	3	{Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
B01D15/3819	5	{of the nucleic acid-nucleic acid binding protein type}
B01J20/3274	7	{Proteins, nucleic acids, polysaccharides, antibodies or antigens}
B01J2219/00722	4	Nucleotides
B01J2219/00729	4	Peptide nucleic acids [PNA]
B01J2231/342	4	Aldol type reactions, i.e. nucleophilic addition of C-H acidic compounds, their R3Si- or metal complex analogues, to aldehydes or ketones
B01J2231/346	4	Mannich type reactions, i.e. nucleophilic addition of C-H acidic compounds, their R3Si- or metal complex analogues to aldimines or ketimines
B01J2231/4277	3	C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues
B01J2231/4283	4	using N nucleophiles, e.g. Buchwald-Hartwig amination
B01J2231/4288	4	using O nucleophiles, e.g. alcohols, carboxylates, esters
B01J2231/4294	4	using S nucleophiles, e.g. thiols
B01L7/52	1	{with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples (amplification or hybridisation processes per se C12Q1/68; controlling sequential reactions for synthesis B01J19/0046)}
C07B59/005	1	{Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids}
C07F9/02	1	Phosphorus compounds (sugar phosphates C07H11/04; nucleotides C07H19/00, C07H21/00; nucleic acids C07H21/00)
C07H		SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
C07H19/00	0	Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides ; Anhydro-derivatives thereof
C07H21/00	0	Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07K14/003	2	{Peptide-nucleic acids (PNAs)}
C12M21/00	0	{Bioreactors or fermenters specially adapted for specific uses (digesters for manure A01C3/023; apparatus for PCR B01L7/52; destroying or transforming solid waste B09B3/00; methods for genetic engineering C12N15/00, C12Q1/68; nucleic acid amplification reactions C12Q1/6844)}
C12M47/06	1	{Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material (lysis of microorganisms C12N1/06; extracting or separating nucleic acids from biological samples C12N15/1003)}
C12N1/08	1	Reducing the nucleic acid content
C12N9/00	0	Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
C12N9/1241	3	{Nucleotidyltransferases (2.7.7)}
C12N9/1258	4	{Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}
C12N9/1264	4	{DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}
C12N9/22	3	Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N15/113)}
C12N15/1003	3	{Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
C12N15/102	3	{Mutagenizing nucleic acids}
C12N15/1062	4	{mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
C12N15/1068	4	{Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
C12N15/1096	3	{cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
C12N15/11	2	DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
C12N15/111	3	{General methods applicable to biologically active non-coding nucleic acids}
C12N15/113	3	Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
C12N15/115	3	Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
C12N15/117	3	Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
C12N2303/00	0	Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids
C12N2310/00	0	Structure or type of the nucleic acid
C12N2310/10	1	Type of nucleic acid
C12N2310/113	3	targeting other non-coding nucleic acids, e.g. antagomirs
C12N2310/12	2	catalytic nucleic acids, e.g. ribozymes
C12N2310/141	3	MicroRNAs, miRNAs
C12N2310/15	2	Nucleic acids forming more than 2 strands, e.g. TFOs
C12N2310/17	2	Immunomodulatory nucleic acids
C12N2310/3181	4	Peptide nucleic acid, PNA
C12N2310/3519	4	Fusion with another nucleic acid
C12N2310/352	3	linked to the nucleic acid via a carbon atom
C12N2310/353	3	linked to the nucleic acid via an atom other than carbon
C12N2320/11	2	for the determination of target sites, i.e. of active nucleic acids
C12N2500/40	2	Nucleotides, nucleosides, bases (cyclic nucleotides C12N2501/01, anti-neoplasic drugs C12N2501/06)
C12N2501/65	1	MicroRNA
C12N2710/00	0	dsDNA viruses
C12N2710/14111	3	Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
C12N2720/00	0	dsRNA viruses
C12N2750/00	0	ssDNA viruses
C12N2760/00	0	ssRNA viruses negative-sense
C12N2770/00	0	ssRNA viruses positive-sense
C12N2795/10011	2	dsDNA Bacteriophages
C12N2795/12011	2	dsRNA Bacteriophages
C12N2795/14011	2	ssDNA Bacteriophages
C12N2795/16011	2	ssRNA Bacteriophages negative-sense
C12N2795/18011	2	ssRNA Bacteriophages positive-sense
C12N2799/021	2	for the expression of a heterologous nucleic acid
C12N2800/00	0	Nucleic acids vectors
C12N2810/6009	3	dsDNA viruses
C12N2810/6027	3	ssDNA viruses
C12P		FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
C12P19/30	3	Nucleotides
C12P19/305	4	{Pyrimidine nucleotides}
C12P19/32	4	having a condensed ring system containing a six-membered ring having two N-atoms in the same ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
C12P19/34	4	Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C12P19/38	3	Nucleosides
C12P19/385	4	{Pyrimidine nucleosides}
C12P19/40	4	having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
C12Q		MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
C12Q1/00	0	Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
C12Q1/68	1	involving nucleic acids
C12Q1/6804	2	Nucleic acid analysis using immunogens (immunoassay G01N33/53)
C12Q1/6806	2	Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
C12Q1/6809	2	Methods for determination or identification of nucleic acids involving differential detection
C12Q1/6825	4	Nucleic acid detection involving sensors
C12Q1/6834	3	Enzymatic or biochemical coupling of nucleic acids to a solid phase
C12Q1/6844	2	Nucleic acid amplification reactions
C12Q1/6865	3	Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
C12Q1/6874	3	involving nucleic acid arrays, e.g. sequencing by hybridisation
C12Q1/6876	2	Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q2500/00	0	Analytical methods involving nucleic acids
C12Q2520/00	0	Reactions involving nucleic acids
C12Q2521/10	1	Nucleotidyl transfering
C12Q2522/10	1	Nucleic acid binding proteins
C12Q2522/101	2	Single or double stranded nucleic acid binding proteins
C12Q2523/109	2	chemical ligation between nucleic acids
C12Q2523/303	2	Applying a physical force on a nucleic acid
C12Q2525/00	0	Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
C12Q2525/101	2	incorporating non-naturally occurring nucleotides, e.g. inosine
C12Q2525/107	2	incorporating a peptide nucleic acid
C12Q2525/121	2	incorporating both deoxyribonucleotides and ribonucleotides
C12Q2525/179	2	incorporating arbitrary or random nucleotide sequences
C12Q2525/185	2	incorporating bases where the precise position of the bases in the nucleic acid string is important
C12Q2525/203	2	incorporating a composite nucleic acid containing a polypeptide sequence other than PNA
C12Q2525/207	2	siRNA, miRNA
C12Q2531/00	0	Reactions of nucleic acids characterised by
C12Q2531/10	1	the purpose being amplify/increase the copy number of target nucleic acid
C12Q2535/00	0	Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
C12Q2535/107	1	Maxam and Gilbert method, i.e. sequential release and detection of nucleotides
C12Q2537/1373	3	Displacement by a nucleic acid
C12Q2541/10	1	the purpose being the selection or design of target specific nucleic acid binding sequences
C12Q2560/00	0	Nucleic acid detection
C12Q2561/00	0	Nucleic acid detection characterised by assay method
C12Q2563/00	0	Nucleic acid detection characterized by the use of physical, structural and functional properties
C12Q2563/116	1	electrical properties of nucleic acids, e.g. impedance, conductivity or resistance
C12Q2563/125	1	the label being enzymatic, i.e. proteins, and non proteins, such as nucleic acid with enzymatic activity
C12Q2563/179	1	the label being a nucleic acid
C12Q2563/185	1	Nucleic acid dedicated to use as a hidden marker/bar code, e.g. inclusion of nucleic acids to mark art objects or animals
C12Q2565/00	0	Nucleic acid analysis characterised by mode or means of detection
C12Q2565/518	2	characterised by the immobilisation of the nucleic acid sample or target
C12Q2565/625	2	being a nucleic acid test strip device, e.g. dipsticks, strips, tapes, CD plates
C12Q2600/178	1	miRNA, siRNA or ncRNA
C12Y101/03028	2	Nucleoside oxidase (1.1.3.28)
C12Y101/03039	2	Nucleoside oxidase (H2O2-forming) (1.1.3.39)
C12Y102/0107	2	Glutamyl-tRNA reductase (1.2.1.70)
C12Y103/01088	2	tRNA-dihydrouridine16/17 synthase (NAD(P)+)(1.3.1.88)
C12Y103/01089	2	tRNA-dihydrouridine47 synthase (NAD(P)+)(1.3.1.89)
C12Y103/0109	2	tRNA-dihydrouridine20a/20b synthase (NAD(P)+)(1.3.1.90)
C12Y103/01091	2	tRNA-dihydrouridine20 synthase (NAD(P)+)(1.3.1.91)
C12Y117/04001	2	Ribonucleoside-diphosphate reductase (1.17.4.1)
C12Y117/04002	2	Ribonucleoside-triphosphate reductase (1.17.4.2)
C12Y201/01029	2	tRNA (cytosine-5-)-methyltransferase (2.1.1.29) (C12Y201/01202 - C12Y201/01204 take precedence)
C12Y201/01031	2	tRNA (guanine-N1-)-methyltransferase (2.1.1.31) (C12Y201/01221, C12Y201/01228 take precedence)
C12Y201/01032	2	tRNA (guanine-N2-)-methyltransferase (2.1.1.32) (C12Y201/01213 - C12Y201/01216 take precedence)
C12Y201/01033	2	tRNA (guanine-N7-)-methyltransferase (2.1.1.33)
C12Y201/01034	2	tRNA (guanosine18-2'-O)-methyltransferase (2.1.1.34)
C12Y201/01035	2	tRNA (uracil-5-)-methyltransferase (2.1.1.35)
C12Y201/01036	2	tRNA (adenine-N1-)-methyltransferase (2.1.1.36) (C12Y201/01217 - C12Y201/0122 take precedence)
C12Y201/01048	2	rRNA (adenine-N6-)-methyltransferase (2.1.1.48) (C12Y201/01181 - C12Y201/01184 take precedence)
C12Y201/01051	2	rRNA (guanine-N1-)-methyltransferase (2.1.1.51) (C12Y201/01187, C12Y201/01188 take precedence)
C12Y201/01052	2	rRNA (guanine-N2-)-methyltransferase (2.1.1.52) (C12Y201/01171 - C12Y201/01174 take precedence)
C12Y201/01055	2	tRNA (adenine-N6-)-methyltransferase (2.1.1.55)
C12Y201/01056	2	mRNA (guanine-N7-)-methyltransferase (2.1.1.56)
C12Y201/01057	2	mRNA (nucleoside-2'-O-)-methyltransferase (2.1.1.57)
C12Y201/01061	2	tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase (2.1.1.61)
C12Y201/01062	2	mRNA (2'-O-methyladenosine-N6-)-methyltransferase (2.1.1.62)
C12Y201/01066	2	rRNA (adenosine-2'-O-)-methyltransferase (2.1.1.66)
C12Y201/01074	2	Methylenetetrahydrofolate--tRNA-(uracil54-C5)-methyltransferase (FADH2-oxidizing) (2.1.1.74)
C12Y201/01166	2	23S rRNA (uridine2552-2'-O-)-methyltransferase (2.1.1.166)
C12Y201/01167	2	27S pre-rRNA (guanosine2922-2'-O-)-methyltransferase (2.1.1.167)
C12Y201/01168	2	21S rRNA (uridine2791-2'-O-)-methyltransferase (2.1.1.168)
C12Y201/0117	2	16S rRNA (guanine527-N7)-methyltransferase (2.1.1.170)
C12Y201/01171	2	16S rRNA (guanine966-N2)-methyltransferase (2.1.1.171)
C12Y201/01172	2	16S rRNA (guanine1207-N2)-methyltransferase (2.1.1.172)
C12Y201/01173	2	23S rRNA (guanine2445-N2)-methyltransferase (2.1.1.173)
C12Y201/01174	2	23S rRNA (guanine1835-N2)-methyltransferase (2.1.1.174)
C12Y201/01176	2	16S rRNA (cytosine967-C5)-methyltransferase (2.1.1.176)
C12Y201/01177	2	23S rRNA (pseudouridine1915-N3)-methyltransferase (2.1.1.177)
C12Y201/01178	2	16S rRNA (cytosine1407-C5)-methyltransferase (2.1.1.178)
C12Y201/01179	2	16S rRNA (guanine1405-N7)-methyltransferase (2.1.1.179)
C12Y201/0118	2	16S rRNA (adenine1408-N1)-methyltransferase (2.1.1.180)
C12Y201/01181	2	23S rRNA (adenine1618-N6)-methyltransferase (2.1.1.181)
C12Y201/01182	2	16S rRNA (adenine1518-N6/adenine1519-N6)-dimethyltransferase (2.1.1.182)
C12Y201/01183	2	18S rRNA (adenine1779-N6/adenine1780-N6)-dimethyltransferase (2.1.1.183)
C12Y201/01184	2	23S rRNA (adenine2085-N6)-dimethyltransferase (2.1.1.184)
C12Y201/01185	2	23S rRNA (guanine2251-2'-O)-methyltransferase (2.1.1.185)
C12Y201/01186	2	23S rRNA (cytidine2498-2'-O)-methyltransferase (2.1.1.186)
C12Y201/01187	2	23S rRNA (guanine745-N1)-methyltransferase (2.1.1.187)
C12Y201/01188	2	23S rRNA (guanine748-N1)-methyltransferase (2.1.1.188)
C12Y201/01189	2	23S rRNA (uracil747-C5)-methyltransferase (2.1.1.189)
C12Y201/0119	2	23S rRNA (uracil1939-C5)-methyltransferase (2.1.1.190)
C12Y201/01191	2	23S rRNA (cytosine1962-C5)-methyltransferase (2.1.1.191)
C12Y201/01192	2	23S rRNA (adenine2503-C2)-methyltransferase (2.1.1.192)
C12Y201/01193	2	16S rRNA (uracil1498-N3)-methyltransferase (2.1.1.193)
C12Y201/01194	2	23S rRNA (adenine2503-C2,C8)-dimethyltransferase (2.1.1.194) (C12Y201/01192, C12Y201/01224 take precedence)
C12Y201/01198	2	16S rRNA (cytidine1402-2'-O)-methyltransferase (2.1.1.198)
C12Y201/01199	2	16S rRNA (cytosine1402-N4)-methyltransferase (2.1.1.199)
C12Y201/012	2	tRNA (cytidine32/uridine32-2'-O)-methyltransferase (2.1.1.200)
C12Y201/01202	2	Multisite-specific tRNA:(cytosine-C5)-methyltransferase (2.1.1.202)
C12Y201/01203	2	tRNA (cytosine34-C5)-methyltransferase (2.1.1.203)
C12Y201/01204	2	tRNA (cytosine38-C5)-methyltransferase (2.1.1.204)
C12Y201/01205	2	tRNA (cytidine32/guanosine34-2'-O)-methyltransferase (2.1.1.205)
C12Y201/01206	2	tRNA (cytidine56-2'-O)-methyltransferase (2.1.1.206)
C12Y201/01207	2	tRNA (cytidine34-2'-O)-methyltransferase (2.1.1.207)
C12Y201/01208	2	23S rRNA (uridine2479-2'-O)-methyltransferase (2.1.1.208)
C12Y201/01209	2	23S rRNA (guanine2535-N1)-methyltransferase (2.1.1.209)
C12Y201/01211	2	tRNA(Ser) (uridine44-2'-O-)-methyltransferase (2.1.1.211)
C12Y201/01213	2	tRNA (guanine10-N2)-dimethyltransferase (2.1.1.213)
C12Y201/01214	2	tRNA (guanine10-N2)-methyltransferase (2.1.1.214)
C12Y201/01215	2	tRNA (guanine26-N2/guanine27-N2)-dimethyltransferase (2.1.1.215)
C12Y201/01216	2	tRNA (guanine26-N2)-dimethyltransferase (2.1.1.216)
C12Y201/01217	2	tRNA (adenine22-N1)-methyltransferase (2.1.1.217)
C12Y201/01218	2	tRNA (adenine9-N1)-methyltransferase (2.1.1.218)
C12Y201/01219	2	tRNA (adenine57-N1/adenine58-N1)-methyltransferase (2.1.1.219)
C12Y201/0122	2	tRNA (adenine58-N1)-methyltransferase (2.1.1.220)
C12Y201/01221	2	tRNA (guanine9-N1)-methyltransferase (2.1.1.221)
C12Y201/01224	2	23S rRNA (adenine2503-C8)-methyltransferase (2.1.1.224)
C12Y201/01225	2	tRNA:m4X modification enzyme (2.1.1.225)
C12Y201/01226	2	23S rRNA (cytidine1920-2'-O)-methyltransferase (2.1.1.226)
C12Y201/01227	2	16S rRNA (cytidine1409-2'-O)-methyltransferase (2.1.1.227)
C12Y201/01228	2	tRNA (guanine37-N1)-methyltransferase (2.1.1.228)
C12Y201/01229	2	tRNA (carboxymethyluridine34-5-O)-methyltransferase (2.1.1.229)
C12Y201/0123	2	23S rRNA (adenosine1067-2'-O)-methyltransferase (2.1.1.230)
C12Y201/01242	2	16S rRNA (guanine1516-N2)-methyltransferase (2.1.1.242)
C12Y201/01256	2	tRNA (guanine6-N2)-methyltransferase (2.1.1.256)
C12Y201/01257	2	tRNA (pseudouridine54-N1)-methyltransferase (2.1.1.257)
C12Y201/0126	2	rRNA small subunit pseudouridine methyltransferase Nep1 (2.1.1.260)
C12Y201/01264	2	23S rRNA (guanine2069-N7)-methyltransferase (2.1.1.264)
C12Y201/02009	2	Methionyl-tRNA formyltransferase (2.1.2.9)
C12Y203/01193	2	tRNA(Met) cytidine acetyltransferase (2.3.1.193)
C12Y204/0111	2	tRNA-queuosine beta-mannosyltransferase (2.4.1.110)
C12Y204/02001	2	Purine-nucleoside phosphorylase (2.4.2.1)
C12Y204/02002	2	Pyrimidine-nucleoside phosphorylase (2.4.2.2)
C12Y204/02005	2	Nucleoside ribosyltransferase (2.4.2.5)
C12Y204/02006	2	Nucleoside deoxyribosyltransferase (2.4.2.6)
C12Y204/02016	2	Urate-ribonucleotide phosphorylase (2.4.2.16)
C12Y204/02019	2	Nicotinate-nucleotide diphosphorylase (carboxylating) (2.4.2.19)
C12Y204/02021	2	Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase (2.4.2.21)
C12Y204/02029	2	tRNA-guanosine34 transglycosylase (2.4.2.29)
C12Y204/02048	2	tRNA-guanine15 transglycosylase (2.4.2.48)
C12Y204/99017	2	S-Adenosylmethionine:tRNA ribosyltransferase-isomerase (2.4.99.17)
C12Y205/01025	2	tRNA-uridine aminocarboxypropyltransferase (2.5.1.25)
C12Y205/01073	2	O-Phospho-L-seryl-tRNA:Cys-tRNA synthase (2.5.1.73)
C12Y205/01075	2	tRNA dimethylallyltransferase (2.5.1.75)
C12Y207/01077	2	Nucleoside phosphotransferase (2.7.1.77)
C12Y207/01143	2	Diphosphate-purine nucleoside kinase (2.7.1.143)
C12Y207/01164	2	O-Phosphoseryl-tRNA(Sec) kinase (2.7.1.164)
C12Y207/04004	2	Nucleoside-phosphate kinase (2.7.4.4)
C12Y207/04006	2	Nucleoside-diphosphate kinase (2.7.4.6)
C12Y207/0401	2	Nucleoside-triphosphate--adenylate kinase (2.7.4.10)
C12Y207/04013	2	(Deoxy)nucleoside-phosphate kinase (2.7.4.13)
C12Y207/06004	2	Nucleotide diphosphokinase (2.7.6.4)
C12Y207/07	1	Nucleotidyltransferases (2.7.7)
C12Y207/07001	2	Nicotinamide-nucleotide adenylyltransferase (2.7.7.1)
C12Y207/07008	2	Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase
C12Y207/07018	2	Nicotinate-nucleotide adenylyltransferase (2.7.7.18)
C12Y207/07028	2	Nucleoside-triphosphate-aldose-1-phosphate nucleotidyltransferase (2.7.7.28)
C12Y207/07031	2	DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase
C12Y207/07037	2	Aldose-1-phosphate nucleotidyltransferase (2.7.7.37)
C12Y207/07046	2	Gentamicin 2''-nucleotidyltransferase (2.7.7.46)
C12Y207/0705	2	mRNA guanylyltransferase (2.7.7.50)
C12Y207/07056	2	tRNA nucleotidyltransferase (2.7.7.56)
C12Y207/07072	2	CCA tRNA nucleotidyltransferase (2.7.7.72)
C12Y207/07079	2	tRNA(His) guanylyltransferase (2.7.7.79)
C12Y208/01004	2	tRNA sulfurtransferase (2.8.1.4)
C12Y209/01001	2	L-Seryl-tRNA(Sec) selenium transferase (2.9.1.1)
C12Y209/01002	2	O-Phospho-L-seryl-tRNA(Sec):L-selenocysteinyl-tRNA synthase (2.9.1.2)
C12Y301/01029	2	Aminoacyl-tRNA hydrolase (3.1.1.29)
C12Y301/03005	2	5'-Nucleotidase (3.1.3.5)
C12Y301/03006	2	3'-Nucleotidase (3.1.3.6)
C12Y301/03007	2	3'(2'),5'-Bisphosphate nucleotidase (3.1.3.7)
C12Y301/03031	2	Nucleotidase (3.1.3.31)
C12Y301/04016	2	2',3'-Cyclic-nucleotide 2'-phosphodiesterase (3.1.4.16)
C12Y301/04017	2	3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
C12Y301/04037	2	2',3'-Cyclic-nucleotide 3'-phosphodiesterase (3.1.4.37)
C12Y301/27009	2	tRNA-intron endonuclease (3.1.27.9)
C12Y301/2701	2	rRNA endonuclease (3.1.27.10)
C12Y302/02001	2	Purine nucleosidase (3.2.2.1)
C12Y302/02002	2	Inosine nucleosidase (3.2.2.2)
C12Y302/02003	2	Uridine nucleosidase (3.2.2.3)
C12Y302/02004	2	AMP nucleosidase (3.2.2.4)
C12Y302/02005	2	NAD+ nucleosidase (3.2.2.5)
C12Y302/02006	2	NAD(P)+ nucleosidase (3.2.2.6)
C12Y302/02007	2	Adenosine nucleosidase (3.2.2.7)
C12Y302/02008	2	Ribosylpyrimidine nucleosidase (3.2.2.8)
C12Y302/02009	2	Adenosylhomocysteine nucleosidase (3.2.2.9)
C12Y302/0201	2	Pyrimidine-5'-nucleotide nucleosidase (3.2.2.10)
C12Y302/02012	2	Inosinate nucleosidase (3.2.2.12)
C12Y302/02013	2	1-Methyladenosine nucleosidase (3.2.2.13)
C12Y302/02014	2	NMN nucleosidase (3.2.2.14)
C12Y302/02016	2	Methylthioadenosine nucleosidase (3.2.2.16)
C12Y302/02022	2	rRNA N-glycosylase (3.2.2.22)
C12Y302/02025	2	N-Methyl nucleosidase (3.2.2.25)
C12Y305/01027	2	N-Formylmethionylaminoacyl-tRNA deformylase (3.5.1.27)
C12Y305/01042	2	Nicotinamide-nucleotide amidase (3.5.1.42)
C12Y306/01006	2	Nucleoside-diphosphatase (3.6.1.6)
C12Y306/01009	2	Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
C12Y306/01015	2	Nucleoside-triphosphatase (3.6.1.15)
C12Y306/01017	2	Bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) (3.6.1.17)
C12Y306/01019	2	Nucleoside-triphosphate diphosphatase (3.6.1.19)
C12Y306/01024	2	Nucleoside phosphoacylhydrolase (3.6.1.24)
C12Y306/01041	2	Bis(5'-nucleosyl)-tetraphosphatase (symmetrical) (3.6.1.41)
C12Y306/01062	2	m7GpppN-mRNA hydrolase (3.6.1.62)
C12Y306/04011	2	Nucleoplasmin ATPase (3.6.4.11)
C12Y504/99012	2	tRNA pseudouridine38-40 synthase (5.4.99.12)
C12Y504/99018	2	5-(Carboxyamino)imidazole ribonucleotide mutase (5.4.99.18)
C12Y504/99019	2	16S rRNA pseudouridine516 synthase (5.4.99.19)
C12Y504/9902	2	23S rRNA pseudouridine2457 synthase (5.4.99.20)
C12Y504/99021	2	23S rRNA pseudouridine2604 synthase (5.4.99.21)
C12Y504/99022	2	23S rRNA pseudouridine2605 synthase (5.4.99.22)
C12Y504/99023	2	23S rRNA pseudouridine1911/1915/1917 synthase (5.4.99.23)
C12Y504/99024	2	23S rRNA pseudouridine955/2504/2580 synthase (5.4.99.24)
C12Y504/99025	2	tRNA pseudouridine55 synthase (5.4.99.25)
C12Y504/99026	2	tRNA pseudouridine65 synthase (5.4.99.26)
C12Y504/99027	2	tRNA pseudouridine13 synthase (5.4.99.27)
C12Y504/99028	2	tRNA pseudouridine32 synthase (5.4.99.28)
C12Y504/99029	2	23S rRNA pseudouridine746 synthase (5.4.99.29)
C12Y504/99042	2	tRNA pseudouridine31 synthase (5.4.99.42)
C12Y504/99043	2	21S rRNA pseudouridine2819 synthase (5.4.99.43)
C12Y504/99044	2	Mitochondrial tRNA pseudouridine27/28 synthase (5.4.99.44)
C12Y504/99045	2	tRNA pseudouridine38/39 synthase (5.4.99.45)
C12Y601/01	1	Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
C12Y601/01001	2	Tyrosine-tRNA ligase (6.1.1.1)
C12Y601/01002	2	Tryptophan-tRNA ligase (6.1.1.2)
C12Y601/01003	2	Threonine-tRNA ligase (6.1.1.3)
C12Y601/01004	2	Leucine--tRNA ligase (6.1.1.4)
C12Y601/01005	2	Isoleucine-tRNA ligase (6.1.1.5)
C12Y601/01006	2	Lysine-tRNA ligase (6.1.1.6)
C12Y601/01007	2	Alanine--tRNA ligase (6.1.1.7)
C12Y601/01009	2	Valine--tRNA ligase (6.1.1.9)
C12Y601/0101	2	Methionine-tRNA ligase (6.1.1.10)
C12Y601/01011	2	Serine--tRNA ligase (6.1.1.11)
C12Y601/01012	2	Aspartate-tRNA ligase (6.1.1.12)
C12Y601/01014	2	Glycine-tRNA ligase (6.1.1.14)
C12Y601/01015	2	Proline--tRNA ligase (6.1.1.15)
C12Y601/01016	2	Cysteine-tRNA ligase (6.1.1.16)
C12Y601/01017	2	Glutamate-tRNA ligase (6.1.1.17)
C12Y601/01018	2	Glutamine--tRNA ligase (6.1.1.18)
C12Y601/01019	2	Arginine--tRNA ligase (6.1.1.19)
C12Y601/0102	2	Phenylalanine-tRNA ligase (6.1.1.20)
C12Y601/01021	2	Histidine-tRNA ligase (6.1.1.21)
C12Y601/01022	2	Asparagine-tRNA ligase (6.1.1.22)
C12Y601/01023	2	Aspartate--tRNA(Asn) ligase (6.1.1.23)
C12Y601/01024	2	Glutamate--tRNA(Gln) ligase (6.1.1.24)
C12Y601/01027	2	O-Phosphoserine--tRNA ligase (6.1.1.27)
C12Y603/04018	2	5-(Carboxyamino)imidazole ribonucleotide synthase (6.3.4.18)
C12Y603/04019	2	tRNA(Ile)-lysidine synthetase (6.3.4.19)
C12Y603/05006	2	Asparaginyl-tRNA synthase (glutamine-hydrolyzing) (6.3.5.6)
C12Y603/05007	2	Glutaminyl-tRNA synthase (glutamine-hydrolyzing) (6.3.5.7)
C40B		COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
C40B40/06	2	Libraries containing nucleotides or polynucleotides, or derivatives thereof
G01N1/30	2	Staining; Impregnating {Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
G01N1/34	2	Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)}
G01N27/3275	5	{Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction}
G01N2030/8827	5	{involving nucleic acids}
G01N33/48721	5	{Investigating individual macromolecules, e.g. by translocation through nanopores (Coulter counters in general G01N15/12; fabrication methods for nanoscale apertures B81B1/00; sequencing of nucleic acids C12Q1/68)}
G01N33/5308	4	{for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
G01N33/6875	4	{Nucleoproteins}
G01N2333/003	2	of Peptide-nucleic acids (PNAs)
G01N2333/9005	2	Enzymes with nucleic acid structure; e.g. ribozymes
G01N2333/91245	5	Nucleotidyltransferases (2.7.7)
G01N2333/91265	7	Polyribonucleotide nucleotidyl transferases, i.e. polynucleotide phosphorylase (2.7.7.8)
G01N2333/9127	7	DNA nucleotidyl-exotransferases, i.e. terminal nucleotidyl transferases (2.7.7.31)
G01N2440/40	1	addition of nucleotides or derivatives, e.g. adenylation, flavin attachment
G16B15/10	1	Nucleic acid folding
G16B20/20	1	Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B30/00	0	ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B35/00	0	ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
Y10S530/821	2	Separation of nucleic acid
Y10S977/704	4	Nucleic acids, e.g. DNA or RNA
Y10S977/711	6	Nucleic acid switching
Y10S977/719	4	Nucleic acid substrate
Y10S977/728	4	Nucleic acids, e.g. DNA or RNA
Y10S977/769	5	formed with nucleic acid
Y10S977/792	6	Nucleic acid array, e.g. human genome array
Y10S977/80	6	Nucleic acid, e.g. DNA or RNA
Y10S977/804	5	Containing nucleic acid
Y10S977/885	4	Via nucleic acid hybridization
Y10S977/946	5	Nucleic acid memory
A01K2267/0387	3	Animal model for diseases of the immune system
A23B4/22	4	Microorganisms; Enzymes; {Antibiotics}
A23B7/155	4	Microorganisms; Enzymes; {Antibiotics}
A23B9/28	4	Microorganisms; Enzymes; {Antibiotics}
A23C9/1322	3	{Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins}
A23C9/158	2	containing vitamins or antibiotics
A23C9/1585	3	{Antibiotics; Bacteriocins; Fungicides from microorganisms}
A23C13/16	2	containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
A23C19/11	3	of antibiotics {or bacteriocins}
A23C2230/15	1	Animal milk with modified composition due to manipulation of the animal, e.g. animal milk comprising antibodies, selection of animals having specific genotypes
A23G1/426	4	{containing vitamins, antibiotics}
A23G3/368	4	{containing vitamins, antibiotics}
A23G4/126	3	{containing vitamins, antibiotics}
A23G9/366	3	{containing vitamins, antibiotics}
A23G2200/04	1	containing vitamins, antibiotics, other medicaments
A23K20/195	2	Antibiotics
A23L3/34635	4	{Antibiotics}
A23L7/101	2	{Addition of antibiotics, vitamins, amino-acids, or minerals}
A23L33/127	2	{Antibiotics}
A23V2200/324	2	having an effect on the immune system
A23V2250/5434	3	Immunoglobulines
A61B5/41	1	{Detecting, measuring or recording for evaluating the immune or lymphatic systems}
A61B5/414	2	{Evaluating particular organs or parts of the immune or lymphatic systems}
A61F2002/30677	5	{Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body}
A61F2310/0097	2	Coating or prosthesis-covering structure made of pharmaceutical products, e.g. antibiotics
A61K35/12	1	Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
A61K2035/122	2	{for inducing tolerance or supression of immune responses}
A61K2035/126	2	{Immunoprotecting barriers, e.g. jackets, diffusion chambers}
A61K35/15	3	Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
A61K35/17	3	Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
A61K35/58	2	Reptiles (antigens from snakes A61K39/38)
A61K36/00	0	Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K39/36)}
A61K38/00	0	Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
A61K38/177	3	{Receptors; Cell surface antigens; Cell surface determinants}
A61K38/1774	4	{Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
A61K39/00	0	Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
A61K39/0001	1	{Archaeal antigens}
A61K39/0002	1	{Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
A61K39/0003	1	{Invertebrate antigens}
A61K39/0005	1	{Vertebrate antigens (from snakes A61K39/38)}
A61K39/0007	2	{Nervous system antigens; Prions}
A61K39/0008	2	{Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
A61K39/0011	2	{Cancer antigens}
A61K39/001102	3	{Receptors, cell surface antigens or cell surface determinants}
A61K39/001111	4	{Immunoglobulin superfamily}
A61K39/001172	4	{sialyl Thomson-nouvelle antigen [sTN]}
A61K39/001178	3	{Tumor rejection antigen precursor [TRAP]}
A61K39/001182	4	{Carcinoembryonic antigen [CEA]}
A61K39/001184	3	{Cancer testis antigens, e.g. SSX, BAGE, GAGE, SAGE}
A61K39/00119	3	{Melanoma antigens}
A61K39/001193	3	{Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP, PSGR}
A61K39/001194	4	{Prostate specific antigen [PSA]}
A61K39/001195	4	{Prostate specific membrane antigen [PSMA]}
A61K39/002	1	Protozoa antigens
A61K39/005	2	Trypanosoma antigens
A61K39/008	2	Leishmania antigens
A61K39/012	2	Coccidia antigens
A61K39/015	2	Hemosporidia antigens, e.g. Plasmodium antigens
A61K39/018	3	Babesia antigens, e.g. Theileria antigens
A61K39/02	1	Bacterial antigens
A61K39/116	2	Polyvalent bacterial antigens
A61K39/12	1	Viral antigens
A61K39/292	3	{Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
A61K39/295	2	Polyvalent viral antigens (vaccinia virus or variola virus A61K39/285); Mixtures of viral and bacterial antigens
A61K39/38	1	Antigens from snakes
A61K39/385	1	Haptens or antigens, bound to carriers
A61K39/39	1	characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K39/395	1	Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K39/39558	3	{against tumor tissues, cells, antigens}
A61K39/39566	3	{against immunoglobulins, e.g. anti-idiotypic antibodies}
A61K39/44	2	Antibodies bound to carriers
A61K2039/505	1	{comprising antibodies}
A61K2039/507	2	{Comprising a combination of two or more separate antibodies}
A61K2039/5154	3	{Antigen presenting cells [APCs], e.g. dendritic cells, macrophages}
A61K2039/5158	3	{Antigen-pulsed cells, e.g. T-cells}
A61K2039/55	1	{characterised by the host/recipient, e.g. newborn with maternal antibodies}
A61K2039/555	1	{characterised by a specific combination antigen/adjuvant}
A61K2039/58	1	{raising an immune response against a target which is not the antigen used for immunisation}
A61K2039/60	1	{characteristics by the carrier linked to the antigen}
A61K2039/6006	2	{Cells (recombinantly expressing antigens A61K2039/5156, A61K2039/523)}
A61K2039/6056	3	{Antibodies}
A61K2039/62	1	{characterised by the link between antigen and carrier}
A61K2039/64	1	{characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
A61K2039/645	2	{Dendrimers; Multiple antigen peptides}
A61K45/05	1	{Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer}
A61K47/552	5	{one of the codrug's components being an antibiotic}
A61K47/555	4	{pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
A61K47/6425	5	{the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
A61K47/646	5	{the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
A61K47/68	3	the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K47/6801	4	{Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
A61K47/6803	5	{Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
A61K47/6809	7	{Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
A61K47/6835	4	{the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}
A61K47/6839	5	{the antibody targeting material from viruses}
A61K47/6841	6	{the antibody targeting a RNA virus}
A61K47/6843	5	{the antibody targeting a material from animals or humans}
A61K47/6845	5	{the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
A61K47/6847	5	{the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}
A61K47/6849	5	{the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
A61K47/6851	5	{the antibody targeting a determinant of a tumour cell}
A61K47/6853	6	{Carcino-embryonic antigens}
A61K47/6871	5	{the antibody targeting an enzyme}
A61K47/6873	5	{the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}
A61K47/6875	5	{the antibody being a hybrid immunoglobulin}
A61K47/6877	6	{the antibody being an immunoglobulin containing regions, domains or residues from different species}
A61K47/6879	6	{the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}
A61K47/6881	5	{Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other}
A61K47/6883	5	{Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}
A61K47/6887	5	{Antibody-chelate conjugates using chelates for therapeutic purposes (radioactive substances, e.g. for use in radio diagnosis or radiotherapy, A61K51/10; antibody-chelates for use in MRI A61K49/14)}
A61K47/6889	4	{Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
A61K47/6891	4	{Pre-targeting systems involving an antibody for targeting specific cells}
A61K47/6893	5	{clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M}
A61K47/6895	5	{Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies}
A61K47/6897	5	{Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies}
A61K47/6898	6	{using avidin- or biotin-conjugated antibodies}
A61K47/6899	5	{Antibody-Directed Enzyme Prodrug Therapy [ADEPT]}
A61K47/6913	5	{the liposome being modified on its surface by an antibody}
A61K47/6929	5	{the form being a nanoparticle, e.g. an immuno-nanoparticle}
A61K49/0058	5	{Antibodies}
A61K49/0428	5	{Surface-modified nanoparticles, e.g. immuno-nanoparticles}
A61K49/049	6	{Surface-modified nanoparticles, e.g. immune-nanoparticles}
A61K49/16	5	Antibodies; Immunoglobulins; Fragments thereof
A61K49/1812	4	{liposomes, polymersomes, e.g. immunoliposomes}
A61K49/1851	7	{having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule (peptide or protein A61K49/1866; polyamino acid A61K49/1872; antibody A61K49/1875)}
A61K49/1875	7	{coated or functionalised with an antibody}
A61K51/06	3	Macromolecular compounds {, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules (peptides, proteins, polyamino acids A61K51/08; antibodies A61K51/10)}
A61K51/088	4	{conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
A61K51/10	4	Antibodies or immunoglobulins; Fragments thereof {, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody}
A61K51/1006	5	{the antibody being against or targeting material from viruses}
A61K51/1027	5	{against receptors, cell-surface antigens or cell-surface determinants}
A61K51/1048	6	{the tumor cell determinant being a carcino embryonic antigen}
A61K51/1051	6	{the tumor cell being from breast, e.g. the antibody being herceptin}
A61K51/1075	5	{the antibody being against an enzyme}
A61K51/1078	5	{the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody}
A61K51/1084	5	{the antibody being a hybrid immunoglobulin}
A61K51/1087	6	{the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins}
A61K51/109	6	{immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies}
A61K51/1093	5	{conjugates with carriers being antibodies}
A61L2300/256	3	Antibodies, e.g. immunoglobulins, vaccines
A61L2300/406	3	Antibiotics
A61L2300/426	2	Immunomodulating agents, i.e. cytokines, interleukins, interferons
A61L2300/438	2	Antigens
A61M1/362	2	{changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity}
A61M2202/0417	4	Immunoglobulin
A61M2202/0419	5	Immunoglobulin G
A61M2202/0445	3	Proteins (immunoglobulin A61M2202/0417; beta-2-microglobulin A61M2202/0421; thrombin A61M2202/0425; haemoglobin A61M2202/0433)
A61P31/00	0	Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P37/00	0	Drugs for immunological or allergic disorders
A61P37/02	1	Immunomodulators
A61P37/04	2	Immunostimulants
A61P37/06	2	Immunosuppressants, e.g. drugs for graft rejection
B01D15/3809	5	{of the antigen-antibody type, e.g. protein A, G, L chromatography}
B01F23/062	2	{Mixing ingredients in very small quantity, adding microingredients or microconcentration, e.g. adding vitamins, minerals, proteins, enzymes, hormones, antibiotics or worm medicines}
B01J20/3274	7	{Proteins, nucleic acids, polysaccharides, antibodies or antigens}
B01J31/00	0	Catalysts comprising hydrides, coordination complexes or organic compounds (catalyst compositions used only in polymerisation reactions C08  {; catalytic antibodies C12N9/0002})
B01J31/067	4	{Molecularly imprinted polymers (catalytic antibodies C12N9/0002)}
C02F2103/343	2	{from the pharmaceutical industry, e.g. containing antibiotics}
C07G11/00	0	Antibiotics
C07K14/4748	5	{Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
C07K14/705	2	Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
C07K14/70503	3	{Immunoglobulin superfamily}
C07K16/00	0	Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies {(antibodies with enzymatic activity, e.g. abzymes C12N9/0002)}
C07K16/28	2	against receptors, cell surface antigens or cell surface determinants
C07K16/2803	3	{against the immunoglobulin superfamily}
C07K16/2869	3	{against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
C07K16/3007	4	{Carcino-embryonic Antigens}
C07K16/34	2	against blood group antigens
C07K16/42	1	against immunoglobulins
C07K16/46	1	Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
C07K16/468	2	{Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
C07K2317/00	0	Immunoglobulins specific features
C07K2317/32	2	specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
C07K2317/50	1	characterized by immunoglobulin fragments
C07K2317/60	1	characterized by non-natural combinations of immunoglobulin fragments
C07K2317/622	3	Single chain antibody (scFv)
C07K2317/624	3	Disulfide-stabilized antibody (dsFv)
C07K2317/70	1	characterized by effect upon binding to a cell or to an antigen
C07K2317/732	3	Antibody-dependent cellular cytotoxicity [ADCC]
C07K2317/75	2	Agonist effect on antigen
C07K2317/76	2	Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K2317/80	1	remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
C07K2317/90	1	characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
C07K2318/00	0	Antibody mimetics or scaffolds
C07K2318/10	1	Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
C07K2318/20	1	Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
C07K2319/30	1	Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
C07K2319/40	1	containing a tag for immunodetection, or an epitope for immunisation
C11D3/3845	4	{Antibodies}
C12M23/20	1	{Material Coatings (immunocoatings C12M25/00)}
C12M25/00	0	{Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings}
C12N1/00	0	Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K35/66, from algae A61K36/02, from fungi A61K36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
C12N5/0634	3	{Cells from the blood or the immune system}
C12N5/0637	5	{Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}
C12N5/064	5	{Immunosuppressive dendritic cells}
C12N7/00	0	Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
C12N9/0002	1	{Antibodies with enzymatic activity, e.g. abzymes}
C12N15/02	1	Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K16/00; apparatus for cell fusion C12M)}
C12N15/117	3	Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
C12N15/8209	6	{Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}
C12N15/821	7	{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}
C12N15/8258	8	{for the production of oral vaccines (antigens) or immunoglobulins}
C12N2015/8518	6	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
C12N2310/17	2	Immunomodulatory nucleic acids
C12N2501/04	1	Immunosuppressors, e.g. cyclosporin, tacrolimus
C12N2501/056	2	Immunostimulating oligonucleotides, e.g. CpG
C12N2502/11	1	blood or immune system cells
C12N2506/11	1	from blood or immune system cells
C12N2740/16011	3	Human Immunodeficiency Virus, HIV
C12N2800/95	1	Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
C12N2810/855	4	from receptors; from cell surface antigens; from cell surface determinants
C12N2810/859	4	from immunoglobulins
C12P19/485	4	{Having two saccharide radicals bound through only oxygen to non-adjacent ring carbons of the cyclohexyl radical, e.g. gentamycin, kanamycin, sisomycin, verdamycin, mutamycin, tobramycin, nebramycin, antibiotics 66-40B, 66-40D, XK-62-2, 66-40, G-418, G-52 (see also C12P19/54)}
C12Q		MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
C12Q1/04	2	Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
C12Q1/6804	2	Nucleic acid analysis using immunogens (immunoassay G01N33/53)
C12Q1/6881	3	for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q1/6886	4	for cancer (immunoassay for cancer G01N33/574)
C12Q1/70	1	involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
C12Q2563/131	1	the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
C12Y207/11009	2	Goodpasture-antigen-binding protein kinase (2.7.11.9)
C12Y304/21077	2	Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
C40B30/04	1	by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N		INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
G01N21/6428	4	{Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
G01N33/50	2	Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
G01N33/5005	3	{involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
G01N33/5047	6	{Cells of the immune system}
G01N33/5097	3	{involving plant cells (immunoassays of plant cells G01N33/56961; unicellular algae, phytoplankton and photosynthetic bacteria in screening assays C12Q1/025)}
G01N33/52	3	Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)}
G01N33/53	3	Immunoassay; Biospecific binding assay; Materials therefor
G01N33/5302	4	{Apparatus specially adapted for immunological test procedures}
G01N33/531	4	Production of immunochemical test materials
G01N33/532	5	Production of labelled immunochemicals
G01N33/536	4	with immune complex formed in liquid phase
G01N33/537	5	with separation of immune complex from unbound antigen or antibody
G01N33/5375	6	{by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning}
G01N33/541	7	Double or second antibody {, i.e. precipitating antibody}
G01N33/543	4	with an insoluble carrier for immobilising immunochemicals
G01N33/54333	7	{Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction}
G01N33/5434	7	{using magnetic particle immunoreagent carriers which constitute new materials per se}
G01N33/5436	5	{with ligand physically entrapped within the solid phase (liposomes G01N33/5432; immunological test elements G01N33/54386)}
G01N33/54387	7	{Immunochromatographic test strips}
G01N33/547	7	with antigen or antibody attached to the carrier via a bridging agent
G01N33/549	6	with antigen or antibody entrapped within the carrier
G01N33/557	4	using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
G01N33/558	4	using diffusion or migration of antigen or antibody {(immunochromatographic test strips G01N33/54387)}
G01N33/561	5	Immunoelectrophoresis
G01N33/563	4	involving antibody fragments
G01N33/564	4	for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
G01N33/57473	5	{involving carcinoembryonic antigen, i.e. CEA}
G01N33/5762	6	{Hepatitis B core antigen}
G01N33/5764	6	{Hepatitis B surface antigen}
G01N33/5765	5	{Hepatitis delta antigen}
G01N33/577	4	involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens; (G01N33/53-G01N33/576 take precedence)}
G01N33/6854	4	{Immunoglobulins}
G01N33/6857	5	{Antibody fragments}
G01N33/6863	4	{Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
G01N33/9493	4	{Immunosupressants}
G01N35/0098	1	{involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation (magnetic particles used in immunoassays G01N33/54326; magnetic separation in general B03C)}
G01N2333/705	2	Assays involving receptors, cell surface antigens or cell surface determinants
G01N2333/70503	3	Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
G01N2333/901	2	Antibodies with enzymatic activity; e.g. abzymes
G01N2400/00	0	Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
G01N2400/02	1	involving antibodies to sugar part of glycoproteins (lectins from plants G01N2333/42, lectins from mammals G01N2333/4724)
G01N2405/00	0	Assays, e.g. immunoassays or enzyme assays, involving lipids (lipopolysaccharides G01N2400/50)
G01N2407/00	0	Assays, e.g. immunoassays or enzyme assays, involving terpenes
G01N2410/00	0	Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
G01N2415/00	0	Assays, e.g. immunoassays or enzyme assays, involving penicillins or cephalosporins
G01N2430/00	0	Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
G01N2446/00	0	Magnetic particle immunoreagent carriers
G01N2446/86	2	the coating being pre-functionalised for attaching immunoreagents, e.g. aminodextran
G01N2446/90	2	characterised by small molecule linker used to couple immunoreagents to magnetic particles
G01N2458/10	1	Oligonucleotides as tagging agents for labelling antibodies
G01N2469/00	0	Immunoassays for the detection of microorganisms
G01N2469/10	1	Detection of antigens from microorganism in sample from host
G01N2469/20	1	Detection of antibodies in sample from host which are directed against antigens from microorganisms
G01N2470/00	0	Immunochemical assays or immunoassays characterised by the reaction format or reaction type
G01N2474/00	0	Immunochemical assays or immunoassays characterised by detection mode or means of detection
G01N2474/10	1	Immunoblots, e.g. Western blot or Dot blot
G01N2474/20	1	Immunohistochemistry assay
G01N2800/24	1	Immunology or allergic disorders (SLE G01N2800/104)
G05B2219/33069	3	Immune algorithm, agent distinguishes self and foreign, lymphocyte, antibody agent
Y10S424/80	1	Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
Y10S424/801	1	involving antibody or fragment thereof produced by recombinant dna technology
Y10S424/802	1	Antibody or antigen-binding fragment thereof that binds gram-positive bacteria
Y10S424/803	1	Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
Y10S424/809	1	involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Y10S424/81	1	involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Y10S424/812	1	Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
Y10S435/961	1	including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
Y10S435/965	1	involving idiotype or anti-idiotype antibody
Y10S435/971	1	Capture of complex after antigen-antibody reaction
Y10S435/972	1	Modified antibody, e.g. hybrid, bifunctional
Y10S436/00	0	Chemistry: analytical and immunological testing
Y10S436/803	1	Stabe free radicals, e.g. spin immunoassay
Y10S436/819	1	Multifunctional antigen or antibody
Y10S436/82	1	Hepatitis associated antigens and antibodies
Y10S436/823	1	Immunogenic carrier or carrier per se
Y10S436/824	1	Immunological separation techniques
Y10S514/885	1	Immune response affecting drug
Y10S524/90	1	Antigen-antibody
Y10S530/866	1	involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Y10S530/867	1	involving immunoglobulin or antibody produced via recombinant dna technology
Y10S530/868	1	involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Y10S930/19	2	Antibiotic
Y10S930/221	3	Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related
Y10S977/904	2	for medical, immunological, body treatment, or diagnosis
Y10S977/918	3	Immunological
Y10T436/00	0	Chemistry: analytical and immunological testing
A01K2217/30	1	Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
A01N63/00	0	Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates (containing compounds of determined constitution A01N27/00 - A01N59/00; unicellular algae A01N65/03)
A01N63/50	1	Isolated enzymes; Isolated proteins (peptides A01N37/46)
A21D8/04	2	treating dough with microorganisms or enzymes
A21D8/042	3	{with enzymes}
A23B4/20	3	Organic compounds; Microorganisms; Enzymes
A23B4/22	4	Microorganisms; Enzymes; {Antibiotics}
A23B5/14	3	Organic compounds; Microorganisms; Enzymes
A23B5/16	4	Microorganisms; Enzymes
A23B7/154	3	Organic compounds; Microorganisms; Enzymes
A23B7/155	4	Microorganisms; Enzymes; {Antibiotics}
A23B9/26	3	Organic compounds; Microorganisms; Enzymes
A23B9/28	4	Microorganisms; Enzymes; {Antibiotics}
A23C3/08	1	by addition of preservatives (additions of microorganisms or enzymes A23C9/12, of other substances A23C9/152)
A23C9/12	1	Fermented milk preparations; Treatment using microorganisms or enzymes
A23C9/1203	2	{Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae}
A23C9/1206	3	{Lactose hydrolysing enzymes, e.g. lactase, beta-galactosidase}
A23C9/1209	3	{Proteolytic or milk coagulating enzymes, e.g. trypsine}
A23C9/1213	3	{Oxidation or reduction enzymes, e.g. peroxidase, catalase, dehydrogenase}
A23C9/1216	3	{Other enzymes}
A23C9/127	2	using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss (A23C9/13 takes precedence)
A23C9/1275	3	{using only lactobacteriaceae for fermentation in combination with enzyme treatment of the milk product; using enzyme treated milk products for fermentation with lactobacteriaceae}
A23C13/16	2	containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
A23C15/065	3	{Addition of a treatment with microorganisms or enzymes; Addition of cultured milk products}
A23C15/123	2	{Addition of microorganisms or cultured milk products; Addition of enzymes; Addition of starter cultures other than destillates}
A23C17/02	1	containing, or treated with, microorganisms or enzymes
A23C19/0245	3	{with immobilized enzymes or microorganisms}
A23C19/032	2	characterised by the use of specific microorganisms, or enzymes of microbial origin
A23C19/0328	3	{Enzymes other than milk clotting enzymes, e.g. lipase, beta-galactosidase}
A23C19/04	2	characterised by the use of specific enzymes of vegetable or animal origin (A23C19/032 takes precedence)
A23C19/041	3	{Proteolytic or milk clotting enzymes from plants or vegetables, e.g. papain, ficin, bromelain}
A23C19/043	3	{Enzymes other than proteolytic enzymes or milk clotting enzymes, e.g. lipase, lysosyme}
A23C19/054	3	{using additives other than acidifying agents, NaCl, CaCl2, dairy products, proteins, fats, enzymes or microorganisms}
A23C19/063	2	{Addition of, or treatment with, enzymes or cell-free extracts of microorganisms}
A23C19/0765	4	{Addition to the curd of additives other than acidifying agents, dairy products, proteins except gelatine, fats, enzymes, microorganisms, NaCl, CaCl2 or KCl; Foamed fresh cheese products}
A23C21/02	1	containing, or treated with, microorganisms or enzymes
A23C21/023	2	{Lactose hydrolysing enzymes, e.g. lactase, B-galactosidase}
A23C2220/10	1	Enzymatic treatment
A23C2220/102	2	Enzymatic treatment in diffusion reactors, e.g. membrane reactors, without immobilisation of the enzyme
A23C2220/104	2	Enzymatic treatment with immobilised enzymes
A23C2220/106	2	Enzymatic treatment with enzymes in microgranules or soluble matrices; Entrapment of enzymes or making enzyme aggregates for delayed solubility; Complexation of enzymes
A23F3/10	3	Fermentation with addition of microorganisms or enzymes
A23F3/166	2	{Addition of, or treatment with, enzymes or microorganisms}
A23F5/163	2	{using enzymes or microorganisms}
A23F5/204	2	{using enzymes or microorganisms}
A23F5/246	2	{Addition of, or treatment with, enzymes or microorganisms (A23F5/163 and A23F5/204 take precedence)}
A23G1/42	3	containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins (containing dairy products A23G1/46)
A23G1/423	4	{containing microorganisms, enzymes}
A23G3/364	3	{containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins}
A23G3/366	4	{containing microorganisms, enzymes}
A23G4/12	2	containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins (containing dairy products A23G4/16)
A23G4/123	3	{containing microorganisms, enzymes}
A23G9/36	2	containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins (characterised by the dairy products used A23G9/40)
A23G9/363	3	{containing microorganisms, enzymes}
A23G2200/02	1	containing microorganisms, enzymes, probiotics
A23J1/125	2	{by treatment involving enzymes or microorganisms (enzymatic hydrolysis of proteins A23J3/34)}
A23J1/148	2	{by treatment involving enzymes or microorganisms (enzymatic hydrolysis of proteins A23J3/34)}
A23J3/34	3	using enzymes
A23K10/14	2	Pretreatment of feeding-stuffs with enzymes
A23K10/30	1	from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms (obtained by microbiological or biochemical processes, e.g. using yeasts or enzymes, A23K10/10)
A23K20/189	2	Enzymes
A23K30/18	3	using microorganisms or enzymes
A23L2/84	2	using microorganisms or biological material, e.g. enzymes
A23L3/3463	3	Organic compounds; Microorganisms; Enzymes
A23L3/3571	4	Microorganisms; Enzymes
A23L5/25	2	{using enzymes}
A23L7/104	2	Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
A23L7/107	3	{Addition or treatment with enzymes not combined with fermentation with microorganisms}
A23L11/33	2	{using enzymes; Enzymatic transformation of pulses or legumes}
A23L13/42	2	{Additives other than enzymes or microorganisms in meat products or meat meals}
A23L13/48	2	{Addition of, or treatment with, enzymes (A23L13/74 takes precedence)}
A23L13/74	3	{using microorganisms or enzymes}
A23L15/25	1	{Addition or treatment with microorganisms or enzymes}
A23L17/65	1	{Addition of, or treatment with, microorganisms or enzymes}
A23L21/11	2	{obtained by enzymatic digestion of fruit or vegetable compositions}
A23L25/40	1	{Fermented products; Products treated with microorganisms or enzymes}
A23L27/215	3	{heated in the presence of reducing sugars, e.g. Maillard's non-enzymatic browning}
A23L29/06	1	{Enzymes}
A23V2250/314	2	Ubiquinone, coenzyme Qn
A24B15/307	5	{using microorganisms or enzymes as catalysts}
A24D3/145	3	{Microbial metabolite, e.g. enzyme}
A61B5/1486	2	using enzyme electrodes, e.g. with immobilised oxidase
A61F2013/00531	3	{for exfoliation (enzymes therefor A61F2013/00927)}
A61F2013/00927	3	{with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors}
A61F2013/8438	4	{being enzymes, e.g. proteolysis, cellulase}
A61K8/66	4	Enzymes
A61K38/005	1	{Enzyme inhibitors (protease inhibitors A61K38/55)}
A61K38/04	1	Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005}; gastrins {A61K38/2207} somatostatins A61K38/31, melanotropins A61K38/34; {protease inhibitors A61K38/55})
A61K38/16	1	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
A61K38/17	2	from animals; from humans {(enzyme inhibitors A61K38/005)}
A61K38/43	2	Enzymes; Proenzymes; Derivatives thereof
A61K38/54	3	Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44-A61K38/46 or A61K38/51-A61K38/53
A61K38/556	3	{Angiotensin converting enzyme inhibitors}
A61K39/001154	3	{Enzymes}
A61K39/3955	3	{against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
A61K39/39583	2	{against materials not provided for elsewhere, e.g. haptens, coenzymes}
A61K47/556	5	{enzyme catalyzed therapeutic agent [ECTA]}
A61K47/65	4	Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K47/67	5	{Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}
A61K47/6815	7	{Enzymes}
A61K47/6871	5	{the antibody targeting an enzyme}
A61K47/6889	4	{Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
A61K47/6899	5	{Antibody-Directed Enzyme Prodrug Therapy [ADEPT]}
A61K51/1075	5	{the antibody being against an enzyme}
A61K2236/19	2	involving fermentation using yeast, bacteria or both; enzymatic treatment (fermentation or enzyme-using processes in general C12P)
A61K2800/78	2	Enzyme modulators, e.g. Enzyme agonists
A61K2800/782	3	Enzyme inhibitors; Enzyme antagonists
A61L2/28	2	Devices for testing the effectiveness or completeness of sterilisation, e.g. indicators which change colour (apparatus involving enzymes or microorganisms C12M1/34; methods involving enzymes or microorganisms C12Q1/00)
A61L12/082	2	{in combination with specific enzymes}
A61L15/38	2	containing enzymes
A61L27/3683	2	{subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
A61L27/3687	3	{characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
A61L33/0011	2	{Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate}
A61L33/0047	2	{Enzymes, e.g. urokinase, streptokinase}
A61L2300/254	3	Enzymes, proenzymes
A61L2300/434	3	of enzymes
A61P1/14	1	Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
A61P1/18	1	for pancreatic disorders, e.g. pancreatic enzymes
A62D3/02	1	by biological methods, i.e. processes using enzymes or microorganisms
B01D15/3814	5	{of the substrate or co-factor - enzyme type}
B01D2252/602	2	Activators, promoting agents, catalytic agents or enzymes
B01D2255/804	2	Enzymatic
B01D2321/166	2	Use of enzymatic agents
B01F23/062	2	{Mixing ingredients in very small quantity, adding microingredients or microconcentration, e.g. adding vitamins, minerals, proteins, enzymes, hormones, antibiotics or worm medicines}
B01J31/003	1	{containing enzymes}
B03D2203/003	1	Biotechnological applications, e.g. separation or purification of enzymes, hormones, vitamins, viruses
B09B3/60	1	Biochemical treatment, e.g. by using enzymes
B09C1/10	1	microbiologically, {biologically} or by using enzymes
C02F3/342	2	{characterised by the enzymes used}
C02F2209/36	1	Biological material, e.g. enzymes or ATP
C04B2103/0001	1	{Living organisms, e.g. microorganisms, or enzymes}
C04B2111/00818	3	{Enzyme carriers}
C05F17/20	1	using specific microorganisms or substances, e.g. enzymes, for activating or stimulating the treatment (use of invertebrates C05F17/05)
C07K		PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
C07K16/00	0	Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies {(antibodies with enzymatic activity, e.g. abzymes C12N9/0002)}
C07K16/40	1	against enzymes
C07K17/00	0	Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof
C07K2299/00	0	Coordinates from 3D structures of peptides, e.g. proteins or enzymes
C07K2317/94	2	Stability, e.g. half-life, pH, temperature or enzyme-resistance
C07K2319/61	1	containing an enzyme fusion for detection (lacZ, luciferase)
C08B		POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
C08J11/105	3	{by treatment with enzymes}
C09B		ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
C09K2208/24	1	Bacteria or enzyme containing gel breakers
C09K2208/26	1	Gel breakers other than bacteria or enzymes
C11B1/025	2	{by enzymes or microorganisms, living or dead}
C11B3/003	1	{by enzymes or microorganisms, living or dead}
C11C1/045	3	{using enzymes or microorganisms, living or dead}
C11D3/386	3	Preparations containing enzymes {, e.g. protease, amylase}
C11D3/38636	4	{containing enzymes other than protease, amylase, lipase, cellulase, oxidase, reductase}
C11D3/38663	4	{Stabilised liquid enzyme compositions (chemically modified or immobilised enzymes C11D3/386, C12N)}
C11D3/38672	4	{Granulated or coated enzymes}
C11D3/38681	4	{Chemically modified or immobilised enzymes}
C11D3/3869	4	{Enzyme enhancers or mediators}
C12C5/004	1	{Enzymes}
C12C5/006	2	{Beta-glucanase or functionally equivalent enzymes}
C12G1/0203	2	{by microbiological or enzymatic treatment}
C12G2200/15	1	Use of particular enzymes in the preparation of wine
C12M1/40	1	Apparatus specially designed for the use of free, immobilised, or carrier-bound enzymes, e.g. apparatus containing a fluidised bed of immobilised enzymes
C12M1/42	1	Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
C12M21/14	1	{for producing enzymes}
C12M21/18	1	{Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes}
C12M35/00	0	{Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion (machines for extracting juice from animal or plant tissue by electroplasmolysis A23N1/006, processes employing electric or wave energy B01J19/08; treatment of microorganisms or enzymes with electrical or wave energy C12N13/00; methods for cell fusion C12N15/02; introduction of foreign genetic material C12N15/87)}
C12M41/38	2	{of metabolites or enzymes in the cells}
C12M41/46	1	{of cellular or enzymatic activity or functionality, e.g. cell viability}
C12M45/09	1	{by enzymatic treatment}
C12N		MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
C12N9/00	0	Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
C12N9/0002	1	{Antibodies with enzymatic activity, e.g. abzymes}
C12N9/107	4	{1,4-Alpha-glucan branching enzyme (2.4.1.18)}
C12N9/6475	7	{Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}
C12N9/6497	7	{Endothelin-converting enzyme (3.4.24.71)}
C12N9/96	1	Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
C12N9/98	1	Preparation of granular or free-flowing enzyme compositions (C12N9/96 takes precedence)
C12N9/99	1	Enzyme inactivation by chemical treatment
C12N11/00	0	Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
C12N11/02	1	Enzymes or microbial cells immobilised on or in an organic carrier
C12N11/098	3	formed in the presence of the enzymes or microbial cells
C12N11/14	1	Enzymes or microbial cells immobilised on or in an inorganic carrier
C12N11/16	1	Enzymes or microbial cells immobilised on or in a biological cell
C12N11/18	1	Multi-enzyme systems
C12N13/00	0	Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
C12N15/10	2	Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
C12N15/1137	4	{against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
C12N15/52	3	Genes encoding for enzymes or proenzymes
C12N15/65	3	using markers (enzymes used as markers C12N15/52)
C12N2501/70	1	Enzymes
C12N2509/00	0	Methods for the dissociation of cells, e.g. specific use of enzymes
C12N2800/95	1	Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
C12P		FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
C12P1/00	0	Preparation of compounds or compositions, not provided for in groups C12P3/00-C12P39/00, by using microorganisms or enzymes
C12P31/005	1	{by fermentation or enzyme-using processes from marine organisms, e.g. Plexaura Homomalla}
C12P41/00	0	Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
C12P2201/00	0	Pretreatment of cellulosic or lignocellulosic material for subsequent enzymatic treatment or hydrolysis
C12Q		MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
C12Q1/00	0	Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
C12Q1/001	1	{Enzyme electrodes}
C12Q1/005	2	{involving specific analytes or enzymes (including groups of enzymes, e.g. oxydases; C12Q1/004 takes precedence)}
C12Q1/007	1	{involving isoenzyme profiles (for detection of an individual isoenzyme C12Q1/25-C12Q1/66)}
C12Q1/008	1	{for determining co-enzymes or co-factors, e.g. NAD, ATP}
C12Q1/25	1	involving enzymes not classifiable in groups C12Q1/26 {- C12Q1/66}
C12Q1/683	4	involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q1/6834	3	Enzymatic or biochemical coupling of nucleic acids to a solid phase
C12Q2326/00	0	Chromogens for determinations of oxidoreductase enzymes
C12Q2334/00	0	O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
C12Q2521/00	0	Reaction characterised by the enzymatic activity
C12Q2521/50	1	Other enzymatic activities
C12Q2521/513	2	Winding/unwinding enzyme, e.g. helicase
C12Q2521/543	2	Immobilised enzyme(s)
C12Q2522/00	0	Reaction characterised by the use of non-enzymatic proteins
C12Q2527/127	1	the enzyme inhibitor or activator used
C12Q2527/149	1	Concentration of an enzyme
C12Q2533/00	0	Reactions characterised by the enzymatic reaction principle used
C12Q2537/1376	3	Displacement by an enzyme
C12Q2561/107	1	Enzyme complementation
C12Q2563/125	1	the label being enzymatic, i.e. proteins, and non proteins, such as nucleic acid with enzymatic activity
C12Y		ENZYMES
C12Y101/98002	2	Glucose-6-phosphate dehydrogenase (coenzyme-F420) (1.1.98.2)
C12Y108/04007	2	Enzyme-thiol transhydrogenase (glutathione-disulfide) (1.8.4.7)
C12Y112/98001	2	Coenzyme F420 hydrogenase (1.12.98.1)
C12Y113/1105	2	Acetylacetone-cleaving enzyme (1.13.11.50)
C12Y114/17004	2	Aminocyclopropanecarboxylate oxidase (1.14.17.4), i.e. ethylene-forming enzyme
C12Y197/01004	2	[Formate-C-acetyltransferase]-activating enzyme (1.97.1.4)
C12Y201/01225	2	tRNA:m4X modification enzyme (2.1.1.225)
C12Y201/01246	2	[Methyl-Co(III) methanol-specific corrinoid protein]:coenzyme M methyltransferase (2.1.1.246)
C12Y201/01247	2	[Methyl-Co(III) methylamine-specific corrinoid protein]:coenzyme M methyltransferase (2.1.1.247)
C12Y201/01251	2	Methylated-thiolcoenzyme M methyltransferase (2.1.1.251)
C12Y201/01253	2	[Methyl-Co(III) tetramethylammonium-specific corrinoid protein]:coenzyme M methyltransferase (2.1.1.253)
C12Y204/01018	2	1,4-Alpha-glucan branching enzyme (2.4.1.18), i.e. glucan branching enzyme
C12Y207/08017	2	UDP-N-acetylglucosamine--lysosomal-enzyme N-acetylglucosaminephosphotransferase (2.7.8.17)
C12Y208/04001	2	Coenzyme-B sulfoethylthiotransferase (2.8.4.1)
C12Y302/01	1	Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
C12Y304/17023	2	Angiotensin-converting enzyme 2 (3.4.17.23)
C12Y304/21086	2	Limulus clotting enzyme (3.4.21.86)
C12Y304/21117	2	Stratum corneum chymotryptic enzyme (3.4.21.117)
C12Y304/23017	2	Pro-opiomelanocortin converting enzyme (3.4.23.17)
C12Y304/24038	2	Gametolysin (3.4.24.38), i.e. cell wall lytic enzyme
C12Y304/24071	2	Endothelin-converting enzyme 1 (3.4.24.71)
C12Y503/04001	2	Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
C12Y603/02019	2	Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
C12Y603/02031	2	Coenzyme F420-0:L-glutamate ligase (6.3.2.31)
C12Y603/02032	2	Coenzyme gamma-F420-2:alpha-L-glutamate ligase (6.3.2.32)
C12Y603/02034	2	Coenzyme F420-1:gamma-L-glutamate ligase (6.3.2.34)
C13B		PRODUCTION OF SUCROSE; APPARATUS SPECIALLY ADAPTED THEREFOR (chemically synthesised sugars or sugar derivatives C07H; fermentation or enzyme-using processes for preparing compounds containing saccharide radicals C12P19/00)
C13B20/002	1	{using microorganisms or enzymes}
C13B35/005	1	{using microorganisms or enzymes}
C13K		SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES (chemically synthesised sugars or sugar derivatives C07H; polysaccharides, e.g. starch, derivatives thereof C08B; malt C12C; fermentation or enzyme-using processes for preparing compounds containing saccharide radicals C12P19/00; production of sucrose C13B)
C14C1/065	2	{Enzymatic unhairing}
C22B3/18	1	with the aid of microorganisms or enzymes, e.g. bacteria or algae
C40B50/06	1	Biochemical methods, e.g. using enzymes or whole viable microorganisms
D06L4/40	1	using enzymes
D06M16/00	0	Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
D06M16/003	1	{with enzymes or microorganisms}
D21C5/005	1	{Treatment of cellulose-containing material with microorganisms or enzymes}
D21H17/005	1	{Microorganisms or enzymes}
G01N		INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
G01N27/3271	5	{Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood (amperometry per se G01N27/49; aspects concerning the enzyme reagent C12Q1/001)}
G01N27/3335	5	{the membrane containing at least one organic component (G01N27/3271 takes precedence; aspects concerning the enzyme reagent in enzyme electrodes C12Q1/001)}
G01N33/50	2	Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
G01N33/535	6	with enzyme label {or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates}
G01N33/573	4	for enzymes or isoenzymes
G01N33/5735	5	{co-enzymes or co-factors, e.g. NAD, ATP}
G01N33/581	4	{with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)}
G01N2333/90	1	Enzymes; Proenzymes
G01N2333/9005	2	Enzymes with nucleic acid structure; e.g. ribozymes
G01N2333/901	2	Antibodies with enzymatic activity; e.g. abzymes
G01N2333/91131	6	Glucan branching enzymes (2.4.1.18)
G01N2333/96469	10	Interleukin 1-beta convertase-like enzymes
G01N2333/96488	10	Phosporamidon sensitive endothelin converting enzymes
G01N2400/00	0	Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
G01N2405/00	0	Assays, e.g. immunoassays or enzyme assays, involving lipids (lipopolysaccharides G01N2400/50)
G01N2407/00	0	Assays, e.g. immunoassays or enzyme assays, involving terpenes
G01N2410/00	0	Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
G01N2415/00	0	Assays, e.g. immunoassays or enzyme assays, involving penicillins or cephalosporins
G01N2430/00	0	Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
G01N2500/02	1	Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
G01N2500/04	1	Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
G03F7/421	3	{using biological means only, e.g. enzymes}
H01L51/0093	2	{Biomolecules or bio-macromolecules, e.g. proteines, ATP, chlorophyl, beta-carotene, lipids, enzymes}
Y10S435/814	1	Enzyme separation or purification
Y10S435/817	1	Enzyme or microbe electrode
Y10S435/963	1	Methods of stopping an enzyme reaction or stabilizing the test materials
Y10S435/964	1	including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
Y10S435/966	1	involving an enzyme system with high turnover rate or complement magnified assay, e.g. multi-enzyme systems
Y10S930/24	2	Enzyme or isoenzyme
Y10S930/25	2	Enzyme inhibitor
Y10S930/32	2	Modification to prevent enzymatic degradation
Y10S977/729	4	From protein or unit thereof, e.g. enzyme or carboxyl group
Y10S977/739	6	Modified with an enzyme
Y10S977/747	6	Modified with an enzyme
Y10S977/898	4	Enzymatic
A01H1/101	2	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine or caffeine}
A01H1/102	3	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
A01H1/104	3	{involving modified lipid metabolism, e.g. seed oil composition}
A01K1/031	3	{Cages for laboratory animals; Cages for measuring metabolism of animals}
A01K2267/0362	3	Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
A24D3/145	3	{Microbial metabolite, e.g. enzyme}
A61B5/083	2	Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
A61B5/4866	2	{Evaluating metabolism (A61B5/083 takes precedence)}
A61P3/00	0	Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
C12M		APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
C12M35/00	0	{Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion (machines for extracting juice from animal or plant tissue by electroplasmolysis A23N1/006, processes employing electric or wave energy B01J19/08; treatment of microorganisms or enzymes with electrical or wave energy C12N13/00; methods for cell fusion C12N15/02; introduction of foreign genetic material C12N15/87)}
C12M41/38	2	{of metabolites or enzymes in the cells}
C12M47/00	0	{Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass (filters in general B01D23/00-B01D41/00)}
C12N15/821	7	{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}
C12N15/8243	7	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
C12N15/8245	8	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
C12N15/8247	8	{involving modified lipid metabolism, e.g. seed oil composition}
C12Q2600/106	1	Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
G01N2033/4977	4	{metabolic gass from microbes, cell cultures, plant tissues and the like}
G01N33/5038	6	{involving detection of metabolites per se}
G01N33/57484	5	{involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites}
G01N2800/04	1	Endocrine or metabolic disorders
G01N2800/042	2	Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
G01N2800/7066	3	Metabolic pathways
G01N2800/7071	4	Carbohydrate metabolism, e.g. glycolysis, gluconeogenesis
G01N2800/7076	4	Amino acid metabolism
G01N2800/708	4	Nitrogen metabolism, e.g. urea cycle
G01N2800/7085	4	Lipogenesis or lipolysis, e.g. fatty acid metabolism
G01R33/485	5	based on chemical shift information {[CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites}
G16B5/00	0	ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
A61K39/001149	4	{Cell cycle regulated proteins, e.g. cyclin, CDC, CDK, INK-CCR}
A61L2400/18	1	Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
C07K14/4738	5	{Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
C07K2317/73	2	Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K2317/74	2	Inducing cell proliferation
C12N2501/18	2	Liver cell growth factor (LCGF, Gly-His-Lys)
C12N2501/405	2	Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
C12N2830/007	1	cell cycle specific enhancer/promoter combination
C12N2840/005	1	cell cycle specific
G01N33/6863	4	{Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
Y10S930/12	2	Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
